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Chapter 1 
Chapter 1 
General Introduction and 
Scope of the Thesis 







1.1   General introduction  
 
The prevalence of obesity is increasing worldwide, especially in the US, where it 
has been reported very recently that the prevalence of obesity and overweight in 
2007-2008 was 68% (1); in the Netherlands it was 51% in 2004 (2). Obesity is 
detrimental to the quality of life and implies high health costs as a consequence of 
its associated low-grade inflammation (3), which is implicated in the pathogenesis 
of obesity-associated diseases, including insulin resistance, diabetes (4) and 
cardiovascular diseases (5;6).  
 
1.2   Etiology of obesity 
 
The etiology of obesity, and consequently its associated diseases, is complex and 
involves biological and life style factors. An important biological factor that 
contributes to the development of obesity and its associated pathologies is the 
white adipose tissue as we will discuss later. The role of life style factors, including 
nutrition, is poorly understood. Regular intake of energy-dense foods and low 
physical activity are associated with the development of obesity. Recently, light 
was shed on an interesting metabolic factor, the colonic metabolism, as we will 
discuss in more details below, which could have important impact for our dietary 
recommendations.  
 
1.2.1   White adipose tissue 
 
White adipose tissue plays a central role in the development of obesity. It is the 
largest organ in the human body where excessive triacylglycerol is stored. In 
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addition, it is an essential endocrine organ that produces various adipokines, which 
are actively involved in the regulation of the whole body homeostasis by 
influencing a variety of biological and physiological processes, including food 
intake, regulation of energy balance, insulin action, lipolysis and lipogenesis. 
During obesity, these processes are dysregulated; leading to an increased 
production of various inflammatory parameters, making adipose tissue the primary 
site of obesity induced chronic inflammation.  
 Adipose tissue is composed of various cell types including adipocytes and 
macrophages, which both are involved in the induction of inflammation. 
Macrophages infiltration into human adipose tissue was shown to be increased 
during obesity (7).   
 
1.2.2   Microbiota 
 
Recently, it has become clear that colonic metabolism is an important factor in the 
contribution to the development of obesity. Both the composition of the colonic 
microbiota and diet are important in this respect. Gordon and colleagues have 
shown that the intestinal bacteria in obese humans and mice differ from those in 
lean individuals. Furthermore, colonization of germ-free mice with microbiota 
from obese mice results in a significantly greater increase in total body fat than 
colonization with microbiota from lean mice (8;9). Conversely, the majority of the 
studies show that dietary fiber increases post-meal satiety, decreases body weight, 
fat mass and the severity of diabetes in humans and mice (10-15). The mechanisms 
by which the intestinal microbiota composition and metabolism can have such 
consequences on obesity-related pathophysiology remain, however, obscure.  
 







1.3   Could propionic acid constitute the link between 
microbiota and obesity?  
 
Fermentation of dietary fiber by the colonic microbiota is the primary source for 
the production of short-chain fatty acids (SCFA), in particular acetic acid, butyric 
acid, and propionic acid (PA). SCFA have recently attracted considerable attention, 
because of their impact on the host’s health. However, most of the studies 
investigated the roles of butyrate alone or mixed with other SCFA in colonic health 
and most of the few studies in which PA was considered alone were investigated in 
ruminants. Although 90% of butyric acid is utilized by colonocytes and very little 
reaches the visceral tissues (16), several peripheral effects of butyrate were 
described. The majority of the PA quantity produced in the colon (20 mmol/kg) 
(17) is absorbed, passes the colonocytes and the viscera, and drains into the portal 
vein. PA can be partially metabolized by the colonocytes; the quantity that is 
utilized by visceral tissues, e.g. omental adipose tissue, has not been examined yet. 
The quantity of PA in the portal vein in non-fasting humans was demonstrated to 
be approximately 0.1 mM (17-19). Together, it is fair to say that PA is a significant 
microbiota-derived metabolite for the analyses of its interaction with the host 
physiology. 
 
1.4   The underlying molecular mechanisms that 
mediates PA signal 
 
In 2003, three independent studies found that PA was the most potent and 
efficacious ligand for GPCR41, and equipotent with acetate for GPCR43 (20-22). 
GPCR41 and GPCR43, like other GPCRs, are linked to GTP-binding proteins (G-
proteins). G-proteins are attached to the cytoplasmic face of the receptor, where 
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they serve as relay molecules functionally coupling the receptors to their 
downstream targets. G-proteins are classified into four major classes, namely Gs, 
Gi/o, Gq/11 and G12/13. Each of them is specific for a particular set of GPCRs and 
a particular set of downstream targets. GPCR41 was shown to initiate its signaling 
through coupling with the Gi/o family of G-proteins (20;21). On the other hand, 
GPCR43 was shown to be coupled to both Gi/o and Gq families of G-proteins (20-
22). GPCR43 was found to be expressed at high levels and GPCR41 was expressed 
to a lesser extent in various immune cells (21). In addition, both of these receptors 
were shown to be present on adipose tissue (20). Taken together, these receptors 
provide an important link in the microbial PA production, adipose tissue and 
inflammation triangle.  
 
1.5   Hypothesis 
 
Taken altogether, one could envision, as illustrated in figure 1, that PA could 
constitute the elusive link between colonic-microbiota metabolism and the biology 
of human adipose tissue including inflammation, insulin sensitivity, lipogenesis 
and adipogenesis, and consequently the whole body homeostasis. 








Figure 1: Schematic representation of our hypothesis. Undigested food reaches the colon 
where it is fermented by the microbiota (1). PA is a primary product of this fermentation 
(2). PA passes the gut epithelium and interacts with adipose tissue (3). It influences the 
physiology of adipose tissue (including inflammation, satiety, insulin action, lipogenesis, 
adipogenesis and lipolysis) and consequently the whole body homeostasis, e.g. in liver (4), 
muscle tissue (5) and central (6) and peripheral (7) nervous system.  
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1.6   Scope of the thesis   
 
Adipose tissue is a primary site of obesity-induced inflammation which is 
emerging as an important contributor to obesity-related diseases. The factors 
influencing adipose tissue-induced inflammation remain poorly understood. 
However, dietary fiber diets appear to be protective to obesity-related diseases, 
suggesting a cross-talk between the colonic metabolism and adipose tissue-induced 
inflammation. Short-chain fatty acids, e.g. propionic acid (PA), are one of the 
principal products of the dietary fiber fermentation by microbiota. This leads us to 
hypothesize that PA could constitute the elusive link between colonic-microbiota 
metabolism and the physiology of human adipose tissue. To test this hypothesis we 
formulated the following research aims, after reviewing the recent knowledge 
about metabolic, immunological and potential adverse effects of PA: 
 
1. To investigate the influence of PA on the production of various markers of 
physiologically relevant functions by human adipose tissue ex vivo, 
including adipokines, cytokines and chemokines. 
2. To determine the contribution of the adipocytes and macrophages to the 
observed anti-inflammatory effects of PA. 
3. To unravel the role of Gi/o-protein in mediating the effects of PA in 
human adipose tissue explants. 
 
To achieve our aims, the following studies have been conducted. 
 
1.6.1   Summary of various aspects of PA 
 
PA has long been underestimated in terms of its physiological impact. Most studies 
addressed the effects of other short chain fatty acids, i.e. butyrate and to a lesser 







extent acetate. Therefore, we made the first review article to discuss various 
aspects of PA in humans and animals, drawing the attention to the recent findings 
and the importance of PA for the health of the host. It has been reported that PA is 
produced by the fermentation of indigested food by the microbiota in the colon, 
which can reach the blood compartment where it reduces (the long chain) fatty 
acids levels and their production in plasma and liver. In addition, it has been 
reported that PA reduces food intake in animals. Although it exerts pronounced 
immunosuppressive actions; however so far no study investigated the influence of 
PA on human adipose tissue inflammation, which is the primary site of obesity 
induced inflammation. Therefore, we conducted the studies as discussed below. 
(Chapter-2). 
 
1.6.2   PA influence on the production of adipokines and the 
involvement of Gi/o-PCR in their responses 
 
We analysed the effect of PA on the production of leptin, resistin and adiponectin 
by women adipose tissue ex vivo, to predict its effect on satiety, pro-inflammation 
and insulin sensitivity, respectively. Leptin production was stimulated in adipose 
tissue by PA treatment, whereas resistin was strongly inhibited and adiponectin 
was not influenced. This may indicate that PA reduces food intake and increases 
energy expenditure (through leptin induction) and it may possess anti-
inflammatory properties (through resistin inhibition). Subsequently we investigated 
the role of Gi/o-proteins in mediating the effects of PA on these adipokines. The 
response of leptin and resistin was mediated via Gi/o-dependent and independent 
pathways, respectively. (chapter-3). 
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1.6.3   PA modulates adipose tissue inflammation via Gi/o-
dependent and independent pathways  
 
The inhibitory effect of PA on the production of the pro-inflammatory adipokine 
(resistin), which we observed in chapter-2, persuaded us to further examine the 
effect of PA on the inflammation of adipose tissue ex vivo. It was revealed that PA 
suppressed the production of various cytokines, chemokines and the ATM markers 
from adipose tissue also via Gi/o-dependent and independent pathways. In 
addition, ATM markers were either not detected or very low in adipocytes 
compared to adipose tissue. Taken together, this implies that non-adipocyte cells, 
most likely ATM, contribute to the immunomodulatory effects of PA. The anti-
inflammatory influence of PA on the adipose compartment may provide a 
mechanistic explanation to the preventive influence of diets leading to the 
increased microbial production of such SCFA on the development of metabolic 
syndrome and indeed we found that PA positively influences the production of the 
markers related to insulin sensitivity, lipogenesis and adipogenesis. (chapter-4).  
 
1.6.4   PA exerts anti-inflammatory effects on human 
macrophages 
 
To evaluate further the role of macrophages, the effect of PA on the secretome of 
human macrophages was investigated via a proteomics approach, SILAC, and 
validated by multiplex-ELISA assay.  Again, PA showed overall anti-inflammatory 
effects, which was demonstrated by the significant inhibition on the release of 17 
inflammatory proteins. (chapter-5). 
 







1.6.5   Human adipocytes exhibit an immune cell like behavior 
 
Our studies so far suggest that adipocytes do not contribute to the effects of PA. 
However, after studying human preadypocytes and adipocytes in depth, we found 
that these cells exhibit an immune cell like behavior.  It was shown, by genomics 
and proteomics approaches, that both preadipocytes and adipocytes produce 
various inflammatory parameters. Interestingly, adipocytes were shown to behave 
as immune cells when they were treated with LPS (induction and reduction of pro-
inflammatory and anti-inflammatory parameters, respectively). Finally, we 
examined whether adipocytes are involved in the initiation of the inflammation 
process and we demonstrated that LPS-stimulated adipocytes indeed recruited 
more CD+4 T-cells. (chapter-6). 
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Undigested food is fermented in the colon by the microbiota and gives rise to 
various microbial metabolites. Short-chain fatty acids (SCFA), including acetic, 
propionic and butyric acid, are the principal metabolites produced. However, most 
of the literature focuses on butyrate and to a lesser extent on acetate; consequently, 
potential effects of propionic acid (PA) on physiology and pathology have long 
been underestimated. It has been demonstrated that PA lowers fatty acids content 
in liver and plasma, reduces food intake, exerts immunosuppressive actions and 
probably improves tissue insulin sensitivity. Thus increased production of PA by 
the microbiota might be considered beneficial in the context of prevention of 
obesity and diabetes type 2. The molecular mechanisms by which PA may exert 
this plethora of physiological effects are slowly being elucidated and include 
intestinal cyclooxygenase enzyme, the G-protein coupled receptors 41 and 43 and 
activation of the peroxisome proliferator-activated receptor γ, in turn inhibiting the 
sentinel transcription factor NF-κB and thus increasing the threshold for 
inflammatory responses in general. Taken together, PA emerges as a major 
mediator in the link between nutrition, gut microbiota and physiology.  
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2.1   Introduction 
 
The link between dietary intake and physiology is long-recognized as evident from 
the age-old adage “you are what you eat” and other colloquial –but not entirely 
unsupported- expressions like “Feed a cold, starve a fever” high light the 
recognition within the general population of the connection between nutrition and 
pathology (1). Indeed many investigators now assume that environmental factors, 
e.g. dietary patterns, are as important as the genetic makeup in the contribution for 
the phenotypes of individuals, especially the propensity for disease. Especially for 
so-called prebiotic diets in general and long chain O-linked oligofructoses 
(fructans) in particular (2), which are associated with general better health, and 
indeed generation of genetically modified crops capable of producing large 
quantities of fructans has become an industry by it self (3). Although many of the 
molecular and immunological aspects by which dietary components could 
influence physiology (4) or even pathology (5) have been uncovered it is fair to say 
that the exact mechanism by which nutritional modification of metabolism of the 
microbiota interacts with the host is still largely obscure at best (6). Here we argue 
that propionic acid is an important link in the nutrition, microbiome and 
physiology triangle. 
 A large body of research indicates that dietary fiber has a profound effect 
on general health. These include the increase of post-meal satiety and the decrease 
of body weight, fat mass and the severity of diabetes (7-12). These effects may be 
contributed via the fermentation of dietary fiber by the colonic microbiota and in 
turn the production of various metabolites, such as SCFA, which are absorbed by 
the host and influence its energy homeostasis (8, 13). The microbiota also 
influences the development of obesity and its associated diseases (14). This 
influence depends on microbiota composition within an individual, which seems to 







be defined via a combination of environmental and genetic factors that could favor 
either obese or lean phenotype (15, 16).  
Fermentation of dietary fiber by the colonic microbiota is the primary 
source for the production of SCFA, i.e. acetic, propionic and butyric acid (figure 
1). SCFA have recently attracted considerable interest, because of their possible 
importance for host health. Most of the studies (and reviews) on the interaction of 
SCFA and mammalian physiology, however, concentrate either solely on the role 
of butyrate alone (17), or on the effects of complex SCFA mixtures, PA mainly 
being investigated in the context of ruminant physiology in general, and on its role 
in liver physiology and metabolism in particular. Although in ruminants PA and 
other SCFA are the major source of energy (PA is the primary precursor for 
glucose production in ruminants), whereas glucose is the major source for humans, 
there is good evidence, as we discuss below, that PA is an important factor in 
human physiology as well. 
Figure 1: The molecular structure of the short chain fatty acids, acetic, propionic and 
butryric acid.  
 
2.2   Propionic acid metabolism 
 
2.2.1   Propionic acid occurrence and production 
 
PA occurs naturally in a few food products; for example PA is present in low 
quantities in milk and relatively higher levels in diary products such as yogurt and 
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cheese, obviously due to bacterial fermentation, mostly by propionibacteria (18, 
19). It is available also as a preservative (E280) in food products, since it has anti-
fungal and anti-bacterial effects (20, 21). These food-sources however, do not lead 
to significant amounts of PA in the human circulation as quantities involved pale in 
comparison to the primary natural source for PA in humans, which is derived from 
the fermentation of undigested food by the colonic microbiota (22). In the colon, 
PA is produced by fermentation of polysaccharides, oligosaccharides, long-chain 
fatty acids, protein, peptides and glycoprotein precursors by the anaerobic colonic 
microbiota (figure 2) (23), although in quantitative terms indigested carbohydrates, 
such as dietary fiber and resistant starch, represents the major source for PA 
production. These substrates are mainly composed of hexoses and pentoses, which 
are fermented by the microbiota through a variety of pathways. Hexoses are broken 
down mainly via the glycolytic pathway or they are converted to 6-phospho-
gluconate and then metabolized via the pentose phosphate pathway, the same 
pathway through which pentoses are metabolized. Pyruvate is the principal 
metabolite of these fermentation reactions; however very little pyruvate is found in 
the colon, because it is converted to a series of end products, such as PA and other 
SCFA. PA is produced from pyruvate via two main pathways: i) Succinate 
decarboxylation pathway, in which CO2 is fixed to pyruvate to form succinate, 
which is subsequently decarboxylated to propionate; and ii) Acrylate pathway, in 
which PA is produced from acrylate with lactate as a precursor (24, 25).   
 









Figure 2: PA metabolism. Undigested food that reaches the colon is broken down by the 
microbiota into hexoses and pentoses molecules, which are further metabolized into 
pyruvate. Pyruvate is converted into PA via (1) Succinate Decarboxylation or (2) Acrylate 
pathways. PA is absorbed by the host, where it induces the production of glucose and 
suppresses the production of fatty acids and cholesterol.*; the effects of PA on the 
production of glucose and cholesterol in humans are controversial. 
 
Despite the technical and ethical issues involved, a few studies measured 
the quantities of PA and other SCFA in human colon and portal vein. The PA 
quantity in the human colon was reported to be 20 mmol/Kg and to depend on the 
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balance between production and absorption (22, 26), the type of microbiota, the 
quantity and the type of the substrate and the gut transit time (24). In contrast to 
butyrate, the majority of the PA produced in the colon is absorbed, passes the 
colonocytes and the viscera, and drains into the portal vein. PA can be partially 
metabolized by colonocytes; however, the quantity that is utilized by visceral 
tissues, e.g. visceral adipose tissue, has not been examined yet. The quantity of PA 
in the portal vein in non-fasting humans was demonstrated to be approximately 0.1 
mM; while it was 3-fold lower in blood derived from fasting humans (22, 27, 28). 
Around 90% of PA quantity is metabolized by the liver and the rest is transported 
into peripheral blood (24), where its quantity in humans was reported 6 µM (27, 
29-31), far in excess of that of butyrate, but lower than acetate. High PA quantities 
also occurred in certain pathological situations, such as gingival inflammation and 
propionic acidemia (32, 33). Together, it is fair to say that propionic acid is likely 
to interact with host physiology. 
 
2.2.2   Propionic acid and glucose metabolism 
 
PA metabolism was extensively studied in ruminants where it is a major glucose 
precursor (34-36). Briefly, PA is converted to propionyl-CoA and enters the Krebs 
cycle at the level of succinyl-CoA (figure 2). This leads to oxaloacetate elevation, 
from which a large amount, in the liver, is converted to glucose. PA is the main 
source for glucose production from SCFA, while cellular biochemistry does not 
allow acetate, butyrate and longer chain fatty acids to contribute to net synthesis of 
glucose. The only pathway for fatty acids with even numbers of carbon atoms is 
via acetyl-CoA and Krebs cycle. When acetyl-CoA enters the cycle the 2 carbon 
atoms are lost as CO2, so no net gain of oxaloacetate occurs (36). Biotin and 
vitamin B12 are essential factors for the anabolic effect (37). This suggests that 
reducing biotin and vitamin B12 increases the PA quantity as under these 







conditions PA is no longer converted to glucose and consequently deficiency in 
these factors lead to reduced energy uptake of the host organism.  Indeed, in severe 
B12 deficiency in sheep, a reduction in feed intake and an elevation of the PA 
quantity in blood was found (38). Much less is known about the effect of PA on 
glucose production in humans (which anyway rely on other sources to maintain 
glucose levels), and existing data are inconsistent (24, 39, 40). 
 
2.2.3   Propionic acid and cholesterol/fatty acid metabolism 
 
Diets supplemented with PA exhibit hypocholesterolemic effects in animals (41, 
42); however, in humans, the effect of PA on cholesterol levels was inconclusive 
(24). Recently, evidence has been accumulating that PA has fatty acid-lowering 
effects. In animals, PA decreased fatty acid production and quantity in the liver 
(43, 44) and in plasma (41, 45). It seems that the effect of PA on fatty acid levels in 
humans is similar to that in animals. Apart from inhibiting the production of fatty 
acids in liver, the observed decreases in fatty acid levels by PA probably also is 
derived from inhibition of lipolysis and the induction of adipogenesis in adipose 
cells and tissue in vitro (46, 47) and in vivo data showed that PA receptor 
(GPCR41)-deficient mice exhibited less adiposity compared to the wild type mice 
(48). Moreover, leptin, which is an adiposity marker, was induced by PA treatment 
of human and mouse adipose tissue (49, 50). In view of the established role of 
circulating fatty acids in vascular pathology, these effects may well contribute to 
the beneficial effects of diets associated with increased PA-production. 
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2.3   Propionic acid’s physiological roles and potential 
applications  
 
2.3.1   Inflammation 
 
It is now well established that the gastrointestinal tract is permanently in a state of 
low grade inflammation (51). Dietary fiber intake, which is the primary substrate 
for PA production, has been associated with a reduction in low grade inflammation 
(8) and in intestinal inflammatory pathogenesis (52-54). PA, as we mentioned 
earlier, has anti-fungal and -bacterial effects (55). Moreover, PA has moderate 
inhibitory activity on cyclooxygenase (56), a major enzyme in the production of 
pro-inflammatory eicosanoids (57). In vitro studies have provided considerable 
evidence that PA has anti-inflammatory properties, apart from its influence on 
eicosanoid metabolism. PA possesses anti-microbial activity against the 
colonization of the gastrointestinal tract by pathogenic bacteria such as Salmonella 
(21), via, for example, the inhibition of the expression of the invasion genes in 
Salmonella typhimurium (58), which are essential to invade and penetrate the 
intestinal epithelium. However, it seems that the inhibition of inflammation by PA 
depends on several factors, such as its concentration, the pH of the extracellular 
milieu and the reason of inflammation, as we describe below. 
The proliferation of human and animal lymphocytes activated by a 
mitogen is inhibited by PA treatment (59, 60). In contrast, Cavaglieri et al reported 
that PA did not influence the proliferation of activated lymphocytes (61). This 
discrepancy might be a consequence of the PA concentration employed in the 
various studies; while Cavaglieri et al used a 2 mM concentration, Wajner et al 
(60) demonstrated that PA concentrations above 2.5 mM were required to reduce 
the proliferation of activated lymphocytes. In addition, Curi et al (59) found that 







PA concentrations equal to or more than 3 mM showed a remarkable high 
inhibition of lymphocyte proliferation, whereas 2 mM produced only a mild 
reduction in lymphocyte proliferation. Likewise, we have shown (49) that 3 mM 
PA or higher inhibited the production of the pro-inflammatory cytokine, resistin, 
by human adipose tissue. Thus at high concentrations PA can directly inhibit the 
adaptive lymphocyte compartment, but comparison to the PA concentrations 
present in the portal and peripheral blood make the physiological relevance of 
these observations doubtful outside the visceral compartment itself.  
Chemically speaking PA is an acid and because of its membrane 
permeable nature higher concentrations of PA may directly exert effects on host 
cell physiology by altering the intracellular pH.  At bay with this notion is that the 
active cellular control of pH is pretty strict and that alternative modes of action 
seem more likely. It was a concern however in the studies of Brunkhorst et al (62) 
and Le Poul (63), who, when trying to demonstrate that PA-induced effects were 
mediated by activated G-proteins, included controls to show that the effects 
observed were not due to extracellular or cytoplasmic pH. Furthermore, in our own 
studies on PA biological activity (49), no evidence of a role for pH-modulation in 
PA effects was found. Conversely, however, there are good data that 
environmental pH determines whether or not PA can exert anti-inflammatory 
actions. Mills et al (64) demonstrated that PA at pH 5.5 inhibited the oxidative 
burst and phagocytosis of bovine neutrophils; while, at pH 6.7 it was stimulatory. 
As most physiological actions of PA can be expected to occur at a more alkaline 
pH, the physiological relevance of these anti-phagocytotic actions of PA is 
uncertain. Wajner et al (60) and Mills et al (64) indicated that the type of stimulant 
could influence the concentration of PA that is needed to suppress inflammation. In 
other words the cause of inflammation, e.g. bacteria, cytokines, adipokines, fatty 
acids and others can determine whether PA can exert its immunosuppressive 
properties, or not. This may clarify the inconsistency of neutrophils response to 
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PA. Indeed, Vinolo et al (65) showed that PA had no effect on phagocytic activity 
and ROS production in rat neutrophils and thus primary efficacy in the innate 
immune system is not targeted by PA, although subsequent changes in innate 
immune cell gene expression might occur: Tedelind et al (66) demonstrated that 
PA inhibited LPS-stimulated TNF-α release by human neutrophils. Moreover, a 
similar phenomenon was shown in endothelial cells; on the one hand Zapolska-
Downar et al (67) demonstrated that PA inhibited the expression of adhesion 
molecules in cytokine-activated human endothelial cells. On the other hand Miller 
et al (68) found no influence of PA on non-activated endothelial cells and in toto a 
picture emerges that direct pathogen clearance by the innate immune system is not 
majorly influenced by PA (which might be in line with its beneficial rather than its 
adverse effects on inflammatory bowel disease, e.g. (69)). Effects in these cells are 
limited to modulation of gene expression. 
In vivo, however, results obtained with SCFA effects on inflammatory 
diseases of the gut are somewhat disappointing, although there is no single study in 
which PA alone was investigated in vivo. Various studies revealed that enemas 
containing SCFA improved the clinical and inflammatory parameters of ulcerative 
colitis (70, 71). In contrast, other studies found only trends toward clinical 
improvement of ulcerative colitis (72, 73). The outcome of the intervention studies 
for diversion colitis was also inconclusive (74, 75). The equivocal results in human 
intervention studies may partly be explained by the differences in the setup of these 
studies, e.g. treatment duration, SCFA concentration and volume, and the small 
number of patients. Thus a convincing demonstration of efficacy of SCFA in 
treating these diseases has not been revealed and further studies are necessary to 
unravel this. Notably, these studies are not reflecting the effects of PA alone, and 
according to the in vitro studies, it is possible that enemas containing PA alone 
could improve the clinical and inflammatory parameters of gut inflammatory 
diseases. In vivo, the effects of PA on other inflammatory diseases, such as low 
grade inflammation, remain also unknown. However, in vitro we (unpublished 







data) demonstrated that PA counteracts the inflammatory reaction in human 
adipose tissue, which is a primary source for obesity induced low grade 
inflammation. 
 
2.3.2   Insulin sensitivity 
 
Inhibitory effects of PA on free fatty acids metabolism and inflammation, which 
we mentioned earlier, suggest that PA could be a potential therapeutic agent to 
improve insulin sensitivity; since free fatty acid-elevation has been demonstrated to 
cause inflammation (76, 77) and vice versa (78, 79) and both lead to insulin 
resistance (79-83). We observed a PA-dependent increase in GLUT-4 in primary 
human adipose explants, which also point in this direction. Moreover, evidence has 
been described for induction of lipogenesis and adipogenesis and inhibition of 
lypolysis (46, 47).  Furthermore, butyrate prevents and reverses diet-induced 
insulin resistance in mice (84). Taken together, good evidence exists that 
systemically relevant concentrations of PA might exert a beneficial effect on 
insulin sensitivity in the adipose compartment and thus PA may well form the 
elusive link between pre- and pro-biotic supplementation and its beneficial effects 
on obesity-related diseases. 
 
2.3.3   Food intake and satiety 
 
A substantial amount of evidence has shown that absorbed PA causes satiety and 
reduces food intake in ruminants (85-87). So far, in humans only two studies 
investigated the role of PA on satiety and both demonstrated that dietary 
supplementation of PA caused satiety (88, 89). The underlying mechanism remains 
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under debate. Studies in ruminants revealed that the mechanism by which PA 
conveys its effect on satiety is not simple and integrates neuronal, endocrine, 
paracrine and autocrine pathways between and within organs and tissues. One of 
the suggested mechanisms was hypertonia (90); however, further work (91) 
disproved that by showing that PA reduced feed intake more than equimolar 
acetate, mannitol, or saline. Anil and Forbes (86) reported in animal studies that 
receptors existed in the liver that were sensitive to PA and that surgical sectioning 
of the hepatic nerve plexus around the wall of the hepatic artery abolished the 
satiety effect of PA. Further splanchnic blockade with anaesthetic, splanchnotomy 
and hepatic vagotomy, as well as with total liver denervation, were shown to 
abolish the reduction in feed intake by portal infusion of PA, although as these 
procedures target innervation of the viscera in toto, other organs/tissues apart from 
the liver may be involved as well (92).  Indeed vagal-innervated visceral adipose 
tissue is a primary endocrine tissue that produces adipokines, which regulate 
satiety and energy homeostasis. It was shown that PA induced the production of 
the satiety hormone leptin by human, mouse and ruminant adipose tissue (46, 49, 
50). In vivo, in mice, PA administered via gavage induced leptin but did not reduce 
food intake. The latter was suggested to be due to gavage-induced stress (46), since 
in the same study, food intake was reduced in mice fed chow containing 3% of 
sodium propionate in diet as compared to controls fed equimolar sodium chloride. 
Leptin is a potent anorexigenic hormone that suppresses food intake through the 
central nervous system (93) and vagal neurons (94). This suggests that visceral 
adipose tissue is another potential mechanism to regulate the satiety induced by PA 
infusion and this notion would fit well with the direct effects of PA on the adipose 
tissues physiology, in particular with respect to release of adipokinetic hormones. 
Finally, food intake could be inhibited by adverse internal cues. For example, it 
was shown that the ingestion of a high quantity of PA by ruminants induced strong 
food aversions apparently due to nausea and discomfort (95-97). 
 







2.4   Potential adverse effects 
 
2.4.1   Propionic acidemia 
 
High quantity of PA could also have potential adverse effects. This has been 
described in the metabolic disorder propinic acidemia,which is caused by defects in 
propionyl-CoA carboxylase enzyme (98). It is a biotin-dependent mitochondrial 
enzyme involved in the metabolism of odd-chain fatty acids and the amino acids 
methionine, threonine, isoleucine and valine by converting propionyl-CoA to 
methylmalonyl-CoA. This defect of the enzyme leads to increased amounts of PA 
and other acids and toxins such as ammonia, which causes food refusal, vomiting, 
immunosuppresion, mental retardation, predisposition for infections and sepsis (99, 
100). However, (101) succeeded to improve these symptoms by liver 
transplantation, while minimal effects were shown on PA quantity. This suggests 
that these symptoms are not due to high PA quantity per sé, but rather due to 
accumulation of various metabolites. Another evidence to support this notion is 
derived from the fact that another organic acidemia (branched chain academia; 
(99)) causes the same symptoms, however without propionic acid accumulation 
(102, 103).  
 
2.4.2   Autism spectrum disorders 
 
Autism is a disorder of neural development including development deficiencies of 
language and social interaction skills, appearance of repetitive and disordered 
movements (104), hyperactivity, sensory disturbances, restricted interests and 
sometimes self injury (105, 106). Very recently and interestingly, it was 
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demonstrated that intraventricular infusions of PA caused behavioral and brain 
abnormalities in rats similar to those seen in humans suffering from autism via 
probably altering brain fatty acid metabolism (107-110). Rather large amounts 
have been used to induce the systems (e.g. 4 μl of 0.26 M solution). It therefore 
remains to be seen that the concentrations that are produced by the microbiota lead 
to similar effects. 
 
2.4.3   Gingival inflammation 
 
Gingival inflammation is an inflammatory process in the gum tissue of the mouth, 
which is caused by the release of short chain fatty acids in millimolar 
concentrations by periodontal bacteria. It was shown that PA is the major 
metabolite produced in vitro (by Prevotella loescheii) (111) and in vivo (112). In 
the in vivo study it was further shown that the subgingival concentration of PA was 
more than 10 fold higher (9.5 mM) in severely diseased patients than in mildly 
diseased patients (0.8 mM), while it was undetectable in the healthy sites of the 
mouth of the same patients. The same group demonstrated in a different study 
(113) that applying PA mixed with other short chain fatty acids into gingival 
margins of designated teeth induced gingival inflammation. The PA effect on gum 
tissue seems contradictory to the pronounced anti-inflammatory effects of PA that 
we discussed earlier; this suggests that PA effect on inflammation depends on the 












2.5   Molecular mechanisms 
 
2.5.1   Cyclooxygenase inhibition 
 
As mentioned, PA has moderate inhibitory activity on cyclooxygenase (56), a 
major enzyme in the production of pro-inflammatory eicosanoids (57) and indeed 
several non steroidal anti-inflammatory drugs (NSAIDs), such as fenoprofen, 
flurbiprofen, ibuprofen and naproxen, are PA analogues (114). In view of the 
concentrations of PA in the colonic intestine, a direct anti-inflammatory effect of 
PA via cyclooxygenase is to be expected and this is a likely mechanism for the 
downregulation of low-grade mucosal inflammation by prebiotic diets. 
Furthermore, both prebiotic diets (2) and cyclooxygenase inhibition (115) are 
associated with reduced incidence of colorectal cancer and thus PA-dependent 
inhibition of cyclooxygenase may well be implicated in this effect as well. This 
notion is strongly supported by the observation of Comalada et al. (116) that 
bacterium-derived SCFA seem directly responsible for anti-carcinogenic effects of 
pre/pro-biotic supplementation in preclinical models of colon cancer. Thus, direct 
modulation of the colonic production of pro-inflammatory cycloocxygenase-
derived eicosanoids may be an important factor by which PA suppresses intestinal 
immunology.  
 
2.5.2   G-protein coupled receptors (GPCR) 
 
In 2003, three independent studies found that PA was the most potent and 
efficacious ligand for GPCR41, and equipotent with acetate for GPCR43 (63, 117, 
118). GPCR41 and GPCR43, like other GPCRs, are linked to GTP-binding 
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proteins (G-proteins). G-proteins are attached to the cytoplasmic face of the 
receptor, where they serve as relay molecules functionally coupling the receptors to 
their downstream targets. G-proteins are classified into four major classes, namely 
Gs, Gi/o, Gq/11 and G12/13. Each of them is specific for a particular set of GPCRs 
and a particular set of downstream targets. GPCR41 was shown to initiate its 
signaling through coupling with the Gi/o family of G-proteins, as evident from the 
absence of a response when transfected cells were treated with a Gi/o-protein-
inhibitor (63, 117). On the other hand, GPCR43 was shown to be coupled to both 
Gi/o and Gq families of G-proteins (63, 117, 118). Notably, neither GCR41 nor 
GPCR43 has been tested for its ability to interact with a full panel of G proteins 
and families.  GPCR43 was found to be expressed at high levels and GPCR41 was 
expressed to a lesser extent in various immune cells (117), providing an obvious 
link between the immune system and microbial PA production. Very recently 
Maslowski et al generated GPCR43 knockout mice and established the importance 
of GPCR43 as an anti-inflammatory chemoattractant receptor (119). In this study, 
GPCR43 knockout mice showed exacerbated inflammation in models of 
inflammatory diseases, i.e. colitis, arthritis and asthma. Wild type germ-free mice, 
which are devoid of bacteria and therefore produce little or no SCFA, showed a 
similar dysregulation of certain inflammatory responses. Furthermore, acetate 
supplementation in drinking water for germ free wild type mice produced a 
reduction in inflammation in the same disease models. As propionic acid is one of 
the two SCFA to reach significant concentrations in the circulation under normal 
conditions, these experiments strongly support the role of propionic acid 
production by the microbiota as an important anti-inflammatory mechanism. 
Despite the dramatic phenotype of the GPRC43 KO, also GPCR41 might 
still turn out to be an important contributor to PA effects in physiology. Both 
receptors are expressed by human adipose tissue (46, 49, 50, 63, 117) leading to 
adipogenesis and inhibition of lipolysis in mouse adipocytes via GPCR43 (46, 47) 
while induction of leptin production, a marker for adiposity, occurs through 







GPCR41 (50). In vivo, GPCR41 was responsible for gut microbiota induced-
adiposity in mice (48). Thus the exact contribution of these two receptors to total 
PA functionality in the body requires further investigation. 
 
2.5.3   PPARγ and NF-κB 
 
The nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) is a 
ligand activated transcription factor, in turn inhibiting the sentinel transcription 
factor, nuclear factor-kappa B (NF-κB) and thus increasing the threshold for 
inflammatory responses in general. Like chemically-related molecules (other fatty 
acids and anti-diabetic drugs, e.g. thiazolidinediones (120)), PA can activate 
PPARγ (our own unpublished results).  PPARγ agonists were shown to inhibit the 
expression of genes regulated via NF-κB; this was through PPARγ-dependent and -
independent mechanisms (121-124). PA down-regulated the activity of NF-κB in 
human colon adenocarcinoma cell line and endothelial cells (66, 67, 125), and 
direct interaction with PPARγ is thus a likely mechanism, providing yet another 
level in which immunity and PA may interact.  
 
2.6   Conclusions and perspectives 
 
PA has long been underestimated in terms of its physiological impact, most studies 
addressing the effects of butyrate and to a lesser extent acetate. Although the latter 
two are probably of principal importance in intestinal physiology, systemically 
they are less likely to have significant effects. PA is mainly produced by the 
fermentation of indigested food by the microbiota in the colon, but can reach the 
blood compartment and the adipose tissue, where it reduces fatty acids levels in 
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plasma via inhibition of lipolysis and induction of lipogenesis in adipose tissue and 
suppression of fatty acid production in liver. We speculate that this is a major 
mechanism by which prebiotics exert their effects on obesity related disease.  
Lowering plasma fatty acids may be especially important, since it is known that 
high plasma fatty acids cause inflammation. In addition, it is known that fatty acids 
and inflammatory factors cause insulin resistance (79-83), so the PA-lowering 
effects on fatty acids and inflammation might lead to the observed improvement in 
insulin sensitivity. These beneficial effects are usually associated with a reduction 
of body weight and indeed it has been demonstrated that PA inhibits food intake 
and increases the duration of satiety via the integrations of neuronal, endocrine, 
paracrine and autocrine pathways between and within organs and tissues. As 
depicted in figure 3, both adipose tissue and liver has been shown to be targets for 
PA. For example, PA influences the production of hormones by adipose tissue, 
such as the induction of leptin. This might contribute to the suppression of food 
intake, since leptin is a potent anorexigenic hormone that suppresses food intake 
through receptors expressed in the central nervous system (93) and vagal neurons, 
which innervates visceral adipose tissue. PA as mechanism for the interaction 
between microbiota and adipose tissue would provide a new paradigm in our view 
of humans as metaorganisms, and further research into this notion is certainly 
called for. 
PA mediates its effects via various molecular mechanisms, which are now 
emerging. Directly, it influences pathogen physiology and down modulates 
intestinal cyclooxygenase activity, via the circulation it can stimulate its receptors 
GPCR41 and GPCR43 and anti-inflammatory effects via the associated signal 
transduction pathways. A last level is the inhibition of NF-κB through PPARγ. 
However, many questions remain. For example, why are there several molecular 
targets for PA and how do they interact with each others to convey PA signaling? 
Also the reason why a lipophilic membrane-permeable compound should have any 
membrane receptors at all remains unclear (126, 127), but this holds true for many 







other lipids as well. Why does PA have two GPCRs? Is the function of GPCR41 
different from that of GPCR43, and if not, then why are these two receptors 
expressed, in some cases, in the same cell type (e.g. adipocytes)? Finally, the 
affinity for PA is low and PA receptors need supraphysiological concentration of 
PA to mediate its effects. This raises the question whether GPCR41 and GPCR43 
are the effective receptors for PA under normal physiological conditions. It is 
possible that PA as well as other SCFA act as surrogate agonists rather than 
endogenous agonists for GPCR41 and GPCR43, or it is possible, but less likely, 
that these receptors are activated in certain pathological situations when the PA 
concentration is unusually high, such as gingival inflammation and propionic 
acidemia. Disregarding these open questions, it is clear that PA is an important part 
of the communication between the microbiota and the physiology of the host and 
more recognition of this notion may prove useful for designing improved 
functional foods. 
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Figure 3: Schematic representation of a hypothetical model to explain the effects of PA. 
PA is produced by the fermentation of undigested food by the colonic microbiota (1). PA 
passes the gut epithelium (2) and reduces the production and the release of FA from (3) 
VAT and liver (4). This might lead to inhibition of inflammation (5) and consequently to 
insulin sensitivity (6). In addition, PA influences the production of hormones by VAT (3) 
and liver (4), which in turn initiates endo- (7), para- (8) and auto-crine (9) and neuronal 
pathways (via vagus and splanchnic nerves) to reduce food intake and to influence other 
metabolic effects (10).  
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Background: Dietary fiber (DF) has been shown to be protective for the 
development of obesity, insulin resistance and type 2 diabetes. Short-chain fatty 
acids, produced by colonic fermentation of DF might mediate this beneficial effect. 
Adipose tissue plays a key role in the regulation of energy homeostasis, therefore, 
we investigated the influence of the short-chain fatty acid propionic acid (PA) on 
leptin, adiponectin and resistin production by human omental (OAT) and 
subcutaneous adipose tissue (SAT). As PA has been shown to be a ligand for G-
protein coupled receptor (GPCR) 41 and 43, we investigated the role of GPCR’s in 
PA signaling. 
Materials and methods: Human OAT and SAT explants were obtained from 
gynecological patients who underwent surgery. Explants were incubated for 24 
hours with PA. Adipokine secretion and mRNA expression were determined by 
ELISA and RT-PCR, respectively. 
Results: We found that PA significantly stimulated leptin mRNA expression and 
secretion by OAT and SAT, whereas it had no effect on adiponectin. Furthermore, 
PA reduced resistin mRNA expression. Leptin induction, but not resistin reduction, 
was abolished by inhibition of Gi/o-coupled GPCR signaling. Moreover, GPCR41 
and GPCR43 mRNA levels were considerably higher in SAT than in OAT. 
Conclusions: We demonstrate that PA stimulates expression of the anorexigenic 
hormone leptin and reduces the pro-inflammatory factor resistin in human adipose 
tissue depots. This suggests that PA is involved in regulation of human energy 
metabolism and inflammation and in this way may influence the development of 
obesity and type 2 diabetes.  
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3.1   Introduction 
 
Obesity and its associated disorders, such as insulin resistance, type 2 diabetes and 
cardiovascular diseases, have become major public health issues. The etiology of 
obesity and insulin resistance is complex and involves life style factors such as 
physical activity and diet. The dietary fiber content (DF) of the diet is one of the 
factors that may influence the development of these diseases. Several studies show 
that consumption of DF prevents accumulation of fat mass (1-3) and increases 
insulin sensitivity (4-6). This may be due to fermentation of DF by the colonic-
microbiota leading to the production of metabolites such as short-chain fatty acids 
(SCFA). SCFA are rapidly absorbed from the colonic lumen and drains through the 
visceral tissues into the portal vein (7).  
 Recently it has been shown that SCFA, including PA, are ligands for the G 
protein-coupled receptor GPCR41 and GPCR43. These receptors, like other GPCR, 
are linked to GTP-binding proteins (G-proteins). G-proteins are attached to the 
cytoplasmic side of the receptor, where they serve as relay molecules functionally 
coupling the receptors to their downstream targets. G-proteins are classified into 
four major classes, namely Gs, Gi/o, Gq/11 and G12/13. Each of them is specific 
for a particular set of GPCR’s and a particular set of downstream targets (8). Both 
GPCR41 and GPCR43 have been shown to be coupled to Gi/o-proteins and are 
present in adipose tissue (9;10), which suggests that adipose tissue is an important 
target for SCFA. As adipose tissue is an endocrine organ that produces a great 
variety of adipokines, that influence metabolism in other organs, it could constitute 
a link between colonic fermentation and peripheral metabolic effects.  
The principal SCFA that are produced in the colon are acetic acid, 
propionic acid and butyric acid. However, most of the studies investigated the 
effects of butyric or acetic acids, while very little is known about effects of PA. In 
addition, 90% of butyric acid is utilized by colonocytes and very little reaches the 







visceral tissues (11), while the majority of acetic acid and PA passes the 
colonocytes and visceral tissues and drains into the portal vein. Recently, it has 
been demonstrated that PA stimulates the production of the anorexigenic adipokine 
leptin in mouse and bovine adipocytes in vitro (12-14) and sheep adipose tissue in 
vivo (15). However, these and most of earlier studies were performed in animals or 
animal tissue, namely ruminants (16). Therefore, the aim of our study was to 
determine the effect of PA on the expression and secretion of adipokines by human 
adipose tissues. As different adipose tissue depots may vary in adipokine secretion 
patterns, we used omental as well as subcutaneous tissue. In addition to leptin, 
which is known to reduce food intake and increase energy expenditure (17) we 
examined the effect on adiponectin and resistin. Adiponectin has insulin sensitizing 
and anti-inflammatory effects (18). Resistin is a pro-inflammatory factor (19-21) 
and recently, it has been shown to be inversely associated with insulin sensitivity 
(22-24). PA is a ligand for GPCR41 and GPCR43. Consequently, we also 
investigated the involvement of the Gi/o-proteins signaling pathway in the 
regulation of adipokine response to PA treatment. 
 
3.2   Materials and methods 
 
3.2.1   Materials 
 
Gentamycin, glucose, PA and pertusis toxin (PTX) were purchased from Sigma 
(Zwijndrecht, The Netherlands). M199 media was purchased from Invitrogen 
(Breda, The Netherlands). GPCR43 and GPCR41 primers were purchased from 
Applied Biosystems (Nieuwerkerk a/d IJssel, The Netherlands); whereas the other 
primers were purchased from Biolegio (Nijmegen, The Netherlands). 
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3.2.2   Human adipose tissue culture 
 
Human omental and abdominal subcutaneous adipose tissue explants as well as 
serum samples were obtained from 28 females, who underwent surgery for 
gynecologic disorders such as myoma, endometriosis and refertilization. None of 
the women had diabetes and their characteristics are summarized in Table 1. The 
study was approved by the local medical ethical committee. 
 
Table 1: Characteristics of adipose tissue donors (N=28). 
 
Characteristics Mean  Range 
Age (years) 45.8 ± 9.3 26-68 
body mass index (BMI, Kg/m2) 26.3 ± 3.3 20.8-33.3 
Waist circumference (WC, cm) 87.3 ± 11.4 57-104 
Hip circumference (HC, cm) 102.4 ± 9.7 82-120 
Waist to hip ratio (WHR) 0.9 ± 0.08 0.54-0.93 
Adipose tissue culture was performed as described previously (25) with slight 
modifications. 0.5 g tissue/5 ml of M199 medium was used and after the last 
washing step, tissue explants were incubated for 24 hours with different PA 
concentrations (0, 0.01, 0.1, 1, 3 and 10 mM). Regarding PTX treatment, adipose 
tissue explants were pre-incubated with PTX (100 ng/ml) for 2 hours. Thereafter, 3 
mM PA was added and incubated for 24 hours. Subsequently, tissue was frozen 
immediately in liquid nitrogen and then stored at -80°C until RNA was isolated. 
Media samples were stored at -80°C prior to ELISA measurements. 
3.2.3   Relative Q-PCR analysis 
 
Total RNA was isolated from adipose tissue by the RNeasy lipid tissue mini kit and 
cDNA was synthesized using the Quantitect kit (Qiagen, Venlo, Netherlands). 
Relative quantification of genes were performed in triplicate with the ABI 7900HT 







sequence detection system for relative real time polymerase chain reaction 
(Taqman, Applied Biosystems) using the ∆∆CT method. The primers pairs and 
probes used are displayed in Table 2. Stability of several housekeeping genes was 
assessed by geNorm analysis software 
(http://medgen.ugent.be/~jvdesomp/genorm/) (26). GAPDH was chosen as the 
most stable housekeeping gene expressed in adipose tissue. PCR was performed 
using TaqMan Universal Master Mix in a total reaction mix volume of 10 μL. The 
PCR conditions were: 15 minutes at 95 °C, 40 cycles of 15 seconds at 95 °C 
followed by 1 minute at 62 °C. 
 
3.2.4   Adipokine protein quantification 
 
Leptin and adiponectin concentrations were measured in culture media by Duoset 
ELISA kit in duplicate, according to the manufacturer’s description (R&D 
Systems, Abingdon, United Kingdom); while resistin was measured in culture 
media and serum by Quantikine ELISA kit (R &D Systems).  
 
3.2.5   Statistics 
 
The average CV of measurements on triplicate incubations was 15.1% for mRNA 
and 28.1% for protein. All data are given as mean ± SEM. Comparison between 
two groups was performed by two-sided paired Student’s t-test. The correlation 
between adipokine mRNA expression and protein level, age and anthropometric 
indices (body mass index (BMI), waist circumference (WC), hip circumference 
(HC) and waist to hip ratio (WHR), was calculated using the Pearson's product 
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moment correlation coefficient test. Results were considered to be statistically 
significant when P < 0.05. 
Table 2: Primer sequences 
*, ID numbers of primer sets from Applied Biosystems. 
Primer ID Primer sequence (5’3’) 
Leptin forward TCA CCA GGA TCA ATG ACA TTT CAC 
Leptin reverse AGC CCA GGA ATG AAG TCC AAA C 
Leptin probe CGC AGT CAG TCT CCT CCA AAC AGA AAG TCA 
Adiponectin forward AGG CCG TGA TGG CAG AGA T 
Adiponectin reverse GTC TCC CTT AGG ACC AAT AAG ACC T 
Adiponectin probe ATC TCC TTT CTC ACC CTT CTC ACC AGG G 
Resistin forward AAG CCA TCA ATG AGA GGA TCC A 
Resistin reverse CTC CAG GCC AAT GCT GCT TA 
Resistin probe CCC TAA ATA TTA GGG AGC CGG CGA CCT C 
GAPDH forward GGT GAA GGT CGG AGT CAA CG 
GAPDH reverse ACC ATG TAG TTG AGG TCA ATG AAG G 




3.3   Results 
 
3.3.1   PA dose-effect relationship with adipokine mRNA 
expression in omental adipose tissue 
 
OAT explants derived from 13 subjects were used to determine the dose-effect 
relationship of PA on adipokine mRNA expression. OAT explants of each subject 
were incubated in triplicate with each concentration of PA for 24 hours. Figure 1 
shows that leptin mRNA expression was significantly stimulated 65% and 100% 







by 1 mM (P = 0.04) and 3 mM (P = 0.006) PA treatments, respectively. In contrast, 
10 mM did not influence leptin mRNA expression. This was also noticed by Le 
Poul et al. (10), who found that 10 mM did not influence neutrophils chemotaxis, 
while 1 mM did. On the other hand, resistin mRNA expression was significantly 
down-regulated 44% (P = 0.0026) and 94% (P < 0.0001) in adipose tissue treated 
with 3 and 10 mM PA, respectively. None of the PA concentrations affected 
adiponectin mRNA expression. 
Figure 1: Dose-response 
curves of PA on 
adipokine production by 
human OAT ex vivo. 
OAT explants of each 
subject were incubated 
in triplicate with each 
concentration of PA for 
24 hours. Leptin (), 
adiponectin () and 
resistin (▲) mRNA 
expression levels were 
determined by RT-PCR 
and depicted as relative 
quantities compared to 
controls (without PA). 
Error bars represent 
SEM.* P < 0.05. 
 
3.3.2   PA effect on adipokine mRNA expression and protein 
secretion by omental adipose tissue  
 
Based on the results above, 3 mM PA was chosen for additional experiments in an 
extended set of explants to investigate the influence of age and anthropometric 
indices of the explant donors on the magnitude of the PA effect on adipokine 
mRNA expression. Moreover, mRNA response was validated on the protein level. 
As represented in Figure 2A, leptin mRNA (N=27) and protein (N=12) levels were 
significantly induced by ~90% (P < 0.0001 for both); whereas resistin expression 
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was significantly reduced (N=27; P < 0.0001) on the mRNA level by 46%, but not 
on the protein level (N=12; P = 0.61). With respect to adiponectin, neither mRNA 
(N=22) nor protein levels (N=12) were changed. Induction of leptin mRNA 
expression after PA treatment of OAT was independent of age or anthropometric 
indices of the donors (Table 3). Basal resistin mRNA expression in OAT was 
positively correlated to the donors’ age (R = 0.49, P = 0.013) but not to 
anthropometric indices, whereas the response of resistin to PA was negative 
correlated to the donors’ age only (R = -0.41, P = 0.03). While there was a positive 
correlation between basal resistin mRNA expression in adipose tissue with age, no 
correlation was observed between serum resistin and age of the explant donors. 
 
Table 3: Analysis of the correlations (r) in OAT between the mRNA expression levels of 
GPCR41, GPCR43 and resistin, resistin level in serum and resistin and leptin responses to 3 

























BMI 0.078 -0.23 0.088 0.29 -0.3 0.037 
WC 0.099 -0.37 0.076 0.17 -0.14 0.11 
HC -0.15 -0.53* 0.22 0.17 -0.17 -0.17 
WHR 0.48* 0.2 -0.083 0.035 -0.025 0.32 
Age -0.023 0.05 0.49* 0.25 -0.41* -0.015 
BMI: Body mass index, HC: hip circumference, WC: waist circumference and WHR: 
waist-hip ratio. * P < 0.05. 
 
3.3.3   PA effect on adipokine mRNA expression and protein 
secretion by subcutaneous adipose tissue 
 
The effect of PA was also investigated on adipokine mRNA and protein levels in 
SAT derived from 5 and 12 subjects, respectively. As depicted in Figure 2B, leptin 
protein and mRNA levels were induced by approximately 35% (P = 0.012 and 
0.027, respectively), resistin was reduced only on the mRNA level by 32% (P = 
0.003) and adiponectin was unaffected both on the mRNA and protein level. 
 
 








Figure 2: PA effects on adipokine production by OAT and SAT ex vivo. 3 mM PA () was 
chosen to validate the effect of PA on adipokine production by OAT (A) and SAT (B) on 
both mRNA and protein levels. OAT and SAT explants of each subject were incubated in 
triplicate with or without 3 mM PA for 24 hours. mRNA expression levels were determined 
by RT-PCR and secreted adipokine levels in the media were determined by ELISA. Results 
are depicted as relative quantities compared to controls (without PA; ). Error bars 
represent SEM. ‡ P < 0.05; * P < 0.001 and + P < 0.0001 and ‡ P < 0.05. 
 
GPCR41 and GPCR43 expression in human omental and subcutaneous 
adipose tissues 
SCFA are ligands for the G protein-coupled receptor GPCR41 and GPCR43 (9;10). 
Therefore, we determined their expression in human OAT and SAT. As shown in 
Figure 3, we found that GPCR41 was expressed at similar levels as GPCR43 in 
each adipose depot. However, levels of both receptors in SAT were approximately 
10-fold higher than in OAT (P = 0.009 and 0.021 for GPCR41 and GPCR43, 
respectively). We also determined whether GPCR41 and GPCR43 expression in 
OAT (N=21, 3 biopsies/subject) was correlated to age and anthropometric indices 
of the donors (Table 3). GPCR41 mRNA expression had a significant and positive 
correlation with WHR (R = 0.48, P = 0.03); whereas GPCR43 expression 
correlated negatively to HC (R = -0.53, P = 0.013). 
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Figure 3: Gene 
expression levels of 
GPCR41 and 
GPCR43 in OAT and 
SAT ex vivo. mRNA 
expression of each 
receptor in SAT was 
determined by RT-
PCR and depicted as 
a relative quantity 
compared to OAT. 
Error bars represent 
SEM. * P < 0.05. 
 
3.3.4   Involvement of Gi/o-protein coupled receptors in the effect 
of PA on leptin and resistin mRNA expression 
 
In mouse adipocytes, it has been shown that PA mediates its effect on leptin 
production via Gi/o-protein coupled receptor (Gi/o-PCR) (12). To determine 
whether PA uses GPCR coupled to Gi/o proteins to affect leptin and resistin 
expression in human adipose tissue, OAT and SAT biopsies taken from six and 
five subjects, respectively, were pretreated with PTX for 2 hours to block the Gi/o 
pathway and then they were treated with or without 3 mM PA for 24 hours. Figure 
4 illustrates that induction of leptin expression by PA was completely abolished by 
PTX pretreatment in both OAT and SAT, while the PA-induced reduction in 
resistin expression was not affected by PTX. PTX treatment also reduced baseline 
leptin expression by approximately 60% and 40% in both OAT and SAT, 
respectively (P = 0.004 and 0.01, respectively). In OAT, PA plus PTX could not 
completely abolish leptin mRNA expression to the level observed with PTX alone.  







Figure 4: Involvement of G-protein coupled receptor(s). The involvement of G-protein 
coupled receptors in mediating PA effects on adipokines expression was determined by 
blocking the Gi/o signaling pathway with PTX. OAT and SAT explants of each subject 
were incubated in triplicate with PTX (100 ng/ml) for 2 hours before incubation for 24 
hours with or without 3 mM PA. mRNA expression levels were determined by RT-PCR 
and depicted as relative quantities compared to controls (without PA). Error bars represent 
SEM. * P ≤ 0.001 vs control; ‡ P < 0.01 vs control; § P < 0.01 vs PA + PTX, # P < 0.05 vs 
PTX and + P < 0.05 vs control. 
 
3.4   Discussion 
 
The present human ex vivo study reveals that PA influences adipokine production 
by both adipose tissue depots (OAT and SAT). Explants were derived from women 
without diabetes with BMI’s ranging between 20.8 and 33.3 Kg/m2. PA induced 
leptin, both on the mRNA and protein level to a similar extent, while it almost 
completely abolished resistin mRNA expression. On the other hand, adiponectin 
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expression was not influenced. The magnitude of the PA effect on leptin was 2.6 
fold higher in OAT compared to SAT and was independent of the degree of 
adiposity and age of the explant donors. Induction of leptin by PA may indicate 
that PA reduces food intake and increases energy expenditure, since leptin is a 
potent anorexigenic hormone (17). In sheep, PA has been shown to induce leptin 
expression in adipose tissue (15) and to reduce food intake (16;27). The observed 
PA-induced reduction of resistin mRNA expression was slightly more pronounced 
in OAT compared to SAT and was negatively associated with age but independent 
of the degree of adiposity of the explant donors. However, on the protein level no 
significant change in resistin expression was seen. This discrepancy between the 
mRNA and the protein level may be explained by the fact that resistin is only 
released from the cell surface membrane or intracellular stores after an 
inflammatory trigger (27). Therefore, a reduction in resistin protein only can be 
observed when cellular stores are depleted. Resistin is pro-inflammatory and, in 
human adipose tissue, is predominantly produced by macrophages (28). Resistin is 
also a marker for insulin resistance in humans (21-23). The PA-induced decrease in 
resistin expression may imply that PA is acting as an anti-inflammatory agent. This 
is in agreement with other studies in which PA has been shown to have anti-
inflammatory effects on human neutrophils and mouse colonic organ cultures (29). 
Furthermore, PA inhibits proliferation of granulocyte/macrophage, hematopoietic 
progenitor cells and lymphocyte activation (30-33). The observed improvement of 
insulin sensitivity in humans after high DF diets (4-6) may be attributed to this 
anti-inflammatory effect of PA since in obese persons adipose tissue inflammation 
and insulin resistance are closely linked (34). In addition to PA, we investigated 
other SCFA. Our preliminary results show that other SCFA may also have an effect 
on adipokine expression (not shown). This is the focus of our future studies. 
The expression of GPCR41 and GPCR43 by human adipose tissue was 
shown to be controversial. For example, Le Poul et al (10) showed that GPCR41 
and GPCR43 were expressed in human adipose tissue, while Hong et al (13) 







showed it was not expressed. In addition, in these previous studies the adipose 
tissue depot was not specified. Our results show that both human adipose tissue 
depots expressed GPCR41 and GPCR43 mRNA. SAT expressed approximately 
10-fold higher amounts of each receptor than OAT, suggesting that SAT is more 
responsive to PA than OAT. However, we found slightly higher responses to PA in 
OAT compared to SAT. Furthermore, we found that GPCR41 mRNA level in OAT 
was positively associated with WHR, as a measure of adiposity, while GPCR43 
was negatively associated with HC (Table 3). However, no correlation with other 
measures of obesity (BMI and WC) was found. Therefore, the relevance of this 
observation remains unclear.  
PTX abolished leptin induction by PA in both human OAT and SAT 
similar to what has been observed in mouse adipocytes (12). This suggests that PA 
regulates leptin production through GPCR coupled to the Gi/o signaling pathway. 
However, the effect of PA on resistin expression was not inhibited by PTX. Le 
Poul et al. (10) showed that there is a unique Gi/o coupling for GPCR41 but for 
GPCR43, a dual coupling exists through Gi/o and Gq. Furthermore, in human 
adipose tissue, resistin is almost exclusively expressed in macrophages (35) while 
leptin expression is specific for adipocytes (36). This may suggest that leptin 
induction by PA is mediated via GPCR41 on adipocytes, coupled to Gi/o, while the 
reduction of resistin by PA is mediated via GPCR43 on resident macrophages, 
coupled to Gq. 
In in vitro studies (30-33), including our study, relatively high PA 
concentrations (1-10 mM) are needed for the observed effects. The question rises 
whether colonic fermentation can provide such concentrations. Due to the absence 
of blood flow, the effective concentration in tissue cultures probably is 
substantially higher than in vivo. The PA concentration in the human colon is 
approximately 20 mmol/kg (7). In ruminants, 50% of absorbed PA reaches the 
portal vein (37), indicating that the remainder is utilized by tissues it encounters 
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such as the colonic wall and possibly OAT. In vivo, the exposure time of adipose 
tissue to PA may be an important factor. Furthermore, effects of different SCFA 
may be additive as acetate, propionate and butyrate all share the same receptors 
(9;10). Further in vivo measurements have to confirm this.  
In conclusion, the present study demonstrates for the first time that PA 
influences adipokine secretion by human adipose tissue. We show that leptin and 
resistin, but not adiponectin production is affected by PA and involves GPCR 
signaling. These findings suggest that modulation of PA quantity through e.g. 
dietary manipulation, prebiotics and probiotics, or dietary supplementation may 
have potential in preventing obesity and its associated complications such as 
inflammation and insulin resistance. 
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Adipose tissue is a primary site of obesity-induced inflammation which is 
emerging as an important contributor to obesity-related diseases. The factors 
influencing adipose tissue-induced inflammation and the resulting pathologies 
remain poorly understood. However, dietary fiber diets appear to be protective, 
suggesting a cross-talk between the colonic metabolism and adipose tissue-induced 
inflammation. Short-chain fatty acids, e.g. propionic acid (PA), are the principal 
products of the dietary fiber fermentation by microbiota. Here we show that the 
treatment of human omental adipose tissue with PA results in a significant 
downregulation of several inflammatory parameters and positively influences 
factors associated with insulin sensitivity, adipogenesis and lipogenesis in this 
tissue via Gi/o-dependent and –independent mechanisms. The negative cross-talk 
between microbiota-produced PA and the adipose tissue inflammatory process 
provides a new paradigm in understanding the relation between the microbiota and 
adipose tissue physiology and suggests its potential in preventing obesity-related 
inflammation and -diseases. 
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4.1   Introduction 
 
Obesity is associated with chronic activation of low-grade inflammation (1), which 
is implicated in the pathogenesis of obesity-associated diseases, including insulin 
resistance, type-2 diabetes (2), cardiovascular diseases (3;4). The etiology of 
obesity and low grade inflammation is complex and involves biological and 
environmental factors. Recently, it has been shown that specific members of the 
microbiota (specifically Firmicutes) in humans are associated with obesity and 
associated pathology (5-7). Furthermore, the colonization of germ-free mice with 
microbiota from obese mice results in significantly greater adiposity than 
colonization with microbiota from lean mice (8). Conversely, so-called prebiotic 
diets in general and long chain O-linked oligofructoses (fructans) in particular (9) 
are associated with general better health, including the decrease in body weight, fat 
mass and the severity of diabetes (10-12). The mechanisms by which the intestinal 
microbiota composition and metabolism can have such large consequences on 
obesity-related pathophysiology remain, however, obscure at best. 
Fermentation of dietary fiber/ resistant starch by the colonic microbiota is 
the primary source for the production of short-chain fatty acids (SCFA), in 
particular acetic acid, butyric acid, and propionic acid. It has been demonstrated 
that SCFA influence the physiology of humans, such as inhibition of inflammation, 
protection from cancer, promotion of satiety and fuels for cells growth (13-15). 
However, most of the studies focused on butyrate and to a lesser extent on acetate, 
while the effects of propionic acid (PA) in humans have remained largely 
unexplored. In this study we focus on PA; the majority of the PA quantity 
produced in the colon (20 mmol/kg) (16) is absorbed, by-passes the colonocytes 
and the viscera, and drains into the portal vein. The PA concentration in the portal 
vein of non-fasting humans was demonstrated to be approximately 0.1 mM (16-
18); however, the quantity that is absorbed or interacts with visceral tissues, e.g. 







omental adipose tissue (OAT), has not been examined yet but is expected to reach 
the millimolar level. Together, it is fair to say that PA is a potential microbiota-
derived metabolite to interact with the physiology of the host tissues, such as OAT. 
Indeed, important evidence for PA to act as an effecter on body-wide 
physiology exists. In 2003, three independent studies found that PA and other 
SCFA are potent and efficacious ligands for the until then orphan G-protein 
coupled receptors 41 (GPCR41) and 43 (GPCR43) (19-21). GPCR41 and GPCR43, 
like other GPCRs, are linked to GTP-binding proteins (G-proteins). G-proteins 
serve as relay molecules functionally coupling the receptors to their downstream 
targets and include four major classes, namely Gs, Gi/o, Gq/11 and G12/13.  Very 
recently Maslowski et al (22) generated GPCR43 knockout mice and established 
the importance of GPCR43 as an anti-inflammatory receptor. GPCR43 knockout 
mice showed exacerbated inflammation in models of inflammatory diseases, i.e. 
colitis, arthritis and asthma. Wild type germ-free mice, which are devoid of 
bacteria and therefore contain little or no SCFA showed a similar dysregulation of 
certain inflammatory responses (16). These experiments strongly support the role 
of PA production by the microbiota as an important anti-inflammatory mechanism. 
As adipose tissue is a major contributor to obesity induced low-grade 
inflammation (23-25) and as both GPCR receptors of PA are present on adipose 
tissue one could envisage that PA could constitute the elusive link between 
colonic-microbiota metabolism and low-grade adipose tissue-induced inflammation 
in humans, prompting direct investigation of this hypothesis. In the present study 
we investigated the influence of PA on several inflammatory parameters in human 
OAT explants. It appeared that physiologically relevant concentrations of PA 
reduced the production in OAT of a panel of chemokines, as well as cytokines and 
adipose tissue macrophage markers. Most of these effects became less pronounced 
when OAT tissue from obese patients was tested for sensitivity to PA. 
Functionally, PA treatment improved insulin sensitivity, adipogenesis and 
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lipogenesis in adipose tissue. At a mechanistic level, we identified Gi/o-dependent 
PA-induced signal transduction as the responsible pathway for at least part of these 
effects. Thus, we provide evidence that a microbial metabolite, in casu PA, can 
counteract the inflammatory reaction in human adipose tissue, providing for the 
first time evidence that microbiological metabolites can influence the physiology of 
the human adipose compartment and suggesting that PA may have potential in 
preventing obesity-related inflammation and diseases.    
 
4.2   Materials and Methods 
 
4.2.1   Materials  
 
Gentamycin, glucose, PA and pertusis toxin (PTX) were purchased from Sigma 
(Zwijndrecht, The Netherlands). M199 media was purchased from Invitrogen 
(Breda, The Netherlands). Preadipocytes and their media were purchased from 
PromoCell (Uithoorn, The Netherlands). CD16A, CD31, CD163, and MMP-9 
primers were purchased from Applied Biosystems (Nieuwerkerk a/d IJssel, The 
Netherlands); whereas the rest of the primers were purchased from Biolegio 
(Nijmegen, The Netherlands). 
 
4.2.2   Human adipose tissue and cell culture  
 
OAT explants were obtained from women who underwent surgery for gynecologic 
disorders such as myoma and prolapse. None of the women had diabetes and their 
anthropometric indices are illustrated in Table 1. The study was approved by the 
local medical ethical committee. Adipose tissue culture was performed as 
described previously (36) with slight modifications. After the last washing step, 
tissue explants were incubated for 24 hours with or without 3 mM PA. Regarding 







PTX treatment, adipose tissue explants were pre-incubated with PTX (100 ng/ml) 
for 2 hours; thereafter, 3 mM PA was added and incubated for 24 hours. 
Subsequently, tissue was snap frozen in liquid nitrogen and then stored at -80°C 
until RNA was isolated. Media samples were stored at -80°C prior to ELISA 
measurements. With respect to human preadipocytes, they were cultured and 
differentiated into adipocytes according to PromoCell instructions. 
 
Table 1: Anthropometric indices of adipose tissue donors. 
Subject ID BMI WHR WC 
S-1 30,44 0,82 95 
S-2 27,46 0,86 90 
S-3 30,85 0,93 95 
S-4 31,89 0,91 104 
S-5 23,59 0,84 82 
 
4.2.3    Relative Q-PCR analysis  
 
Total RNA was isolated by the RNeasy lipid tissue mini kit and cDNA was 
synthesized using the Quantitect kit (both from Qiagen, Venlo, Netherlands). 
Relative quantification of genes were performed in triplicate with the ABI 7900HT 
sequence detection system for relative real time polymerase chain reaction 
(Taqman, Applied Biosystems) using the ∆∆CT method. The primers pairs and 
probes used are displayed in Table 2. Stability of several housekeeping genes was 
assessed by geNorm analysis software 
(http://medgen.ugent.be/~jvdesomp/genorm/) (37). GAPDH was chosen as the 
most stable housekeeping gene expressed in adipose tissue. PCR was performed 
using TaqMan Universal Master Mix in a total reaction mix volume of 10 μL. The 
PCR conditions were: 15 minutes at 95 °C, 40 cycles of 15 seconds at 95 °C 
followed by 1 minute at 62 °C. 
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Table 2: The sequences of the primers. 
Primer ID Primer sequence (5’(3’) 
GAPDH forward GGT GAA GGT CGG AGT CAA CG 
GAPDH backward ACC ATG TAG TTG AGG TCA ATG AAG G 
GAPDH probe CGC CTG GTC ACC AGG GCT GC 
IRS-1 forward CCA CTC GGA AAA CTT CTT CTT CAT 
IRS-1 backward GAG TCA TCC ACC TGC ATC CA 
IRS-1 probe AGG TGG GCC GTT CTG CCG TG 
GLUT4 forward GCT GTG GCT GGT TTC TCC AA 
GLUT4 backward CCC ATA GCC TCC GCA ACA TA 
GLUT4 probe CGA GCA ACT TCA TCA TTG GCA TGG GTT 
FASN forward GCA AAT TCG ACC TTT CTC AGA AC 
FASN backward GGA CCC CGT GGA ATG TCA 
FASN probe CCC GCT CGG CAT GGC TAT C 
LPL forward TGG AGA TGT GGA CCA GCT AGT G 
LPL backward CAG AGA GTC GAT GAA GAG ATG AAT G 
LPL probe CTC CCA CGA GCG CT 
SREBP1c forward GGA TTG CAC TTT CGA AGA CAT G 
SREBP1c backward AGC ATA GGG TGG GTC AAA TAG G 
SREBP1c probe CAG CTT ATC AAC AAC CAA GAC AGT GAC TTC CC 
Pref-1 forward TCC TGC GCG TCC TCT TG 
Pref-1 backward GAA GCA TTC AGC CCC ATA GG 
Pref-1 probe CTG CTG GCT TTC GGC CAC AGC 
CD163 forward TGC AGA AAA CCC CAC AAA AAG 
CD163 backward CAA GGA TCC CGA CTG CAA TAA 




*, ID numbers of primer sets from Applied Biosystems. 
4.2.4   Protein quantification  
 
Secreted chemokines and cytokines were measured in culture media by multiplex-
ELISA assay according to the manufacturer’s description (Bio-Rad, Hercules, CA, 
USA). 
 







4.2.5   Statistics  
 
Comparison between two groups was performed by two-sided paired Student’s t-
test. Results were considered to be statistically significant at P < 0.05. The 
correlation between the production level of the examined parameters and 
anthropometric indices (i.e. body mass index (BMI), waist circumference (WC) 
and waist to hip ratio (WHR)) was calculated using the Pearson's product moment 
correlation coefficient test.  
 
4.3   Results 
 
4.3.1   PA counteracts inflammation in human adipose tissue  
 
Adipose tissue is an essential endocrine organ that produces various adipokines, 
which are involved in the regulation of various physiological functions. During 
obesity, the production of several inflammatory parameter (23-25) and the 
infiltration of inflammatory cells is increased in adipose tissue, providing clear 
evidence that adipose tissue-induced inflammation is a principal factor in the 
pathogenesis of obesity related diseases. Concomitantly, it is becoming clear that 
especially prebiotic diets, favoring the production of SCFA by the colonic 
microbiota, are associated with reduced obesity related diseases (26;27). Hence, we 
investigated the influence of 3 mM PA, a microbiota derived metabolite, on the 
production of several inflammatory parameters in human explants derived from 5 
women, in triplicate. We found that PA treatment significantly (P < 0.05) 
downregulated the secretion of interleukin-10 (IL-10), tumor necrosis factor-α 
(TNF-α), granulocyte-colony stimulating factor (G-CSF), interferon-gamma-
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induced protein (IP-10), Macrophage Inflammatory Proteins-1α and -1β (MIP-1α 
and MIP-1β) and “regulated upon activation, normal T cell expressed and secreted” 
(RANTES) approximately by 2 fold (Figure 1), while IL-1β and IL-4 were not 
influenced and IL-12 and IL-13 were not detected. It appeared that especially the 
inhibition of IL-10 and TNF-α was positively associated with the indicators of 
obesity, while the inhibition of G-CSF, MIP-1α, MIP-1β and RANTES was 
negatively associated and the response of IP-10 was not associated with any 
indicators (Figure 2). Moreover, the secretion of IL-10, MIP-1α, MIP-1β, RANTES 
and TNF-α from unstimulated explants were associated positively with some of the 
indicators of obesity, while G-CSF and IP-10 were negatively associated (Figure 
3).  
Figure 1: The influence of PA on the secretion of chemokines and cytokines by omental 
human adipose tissue. OAT explants of each subject were incubated in triplicate with or 
without 3 mM PA for 24 hours. PA inhibited the secretion of IL10, IP-10, G-CSF, MIP-1α, 
MIP-1β, RANTES and TNF-α, while it had no effect on IL-1β and IL-4. Secreted quantities 
of chemokines and cytokine in the media were determined by multiplex-ELISA. Results are 
depicted as relative quantities (RQ) compared to the control (without PA; C). *, P < 0.05. 
M, mean. 








Figure 2: The association between the indicators of obesity and the response of 
chemokines and cytokines to PA treatment. OAT explants of each subject were incubated 
in triplicate with or without 3 mM PA for 24 hours. The correlation coefficients (R) were 
determined between percentage of inhibition and the indicators of obesity, i.e.  BMI, WC 
and WHR. The inhibition of IL-10 and TNF-α was positively associated with at least 2 
indicators of obesity, while the inhibition of G-CSF, MIP-1α, MIP-1β and RANTES was 
negatively associated and the response of IP-10 was not associated with any indicators. 
Secreted quantities of chemokines and cytokine in the media were determined by 
multiplex-ELISA. Results are depicted as a percentage of inhibition compared to the 
control (without PA; C), which was set to a 100%.  
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Figure 3: The association between the indicators of obesity and the basal quantity of 
chemokines and cytokines. Secreted quantities of chemokines and cytokines in the media 
from unstimulated OAT explants (in triplicate) derived from 5 subjects were determined by 
multiplex-ELISA and correlated to the indicators of, i.e. BMI, WC and WHR. The 
secretion of IL-10, MIP-1α, MIP-1β, RANTES and TNF-α was associated positively with 
at least one of these indicators, while G-CSF and IP-10 were negatively associated.  
 
The observed inhibitory effect on the examined chemokines suggests that PA 
inhibits the recruitment, growth and/or activity of macrophages and/or 
transdifferentiation of preadipocytes into macrophages. To further clarify this, we 







determined the effects of PA on the mRNA expression of adipose tissue 
macrophages (ATM) markers, CD16, CD31, CD163 and metalloproteinase 9 
(MMP-9) (28-31) by human adipose tissue explants obtained from 4 women. 3 
explants per subject were incubated with or without PA. As illustrated in Figure 4, 
the treatment significantly downregulated the mRNA expression of CD16, CD31, 
CD163 and MMP-9, by approximately 30%, 15%, 50%, and 59%, respectively (P 
< 0.05).  
Figure 4: The influence of PA on the mRNA expression of adipose tissue macrophage 
related markers. OAT explants of each subject were incubated in triplicate with or without 
3 mM PA for 24 hours. PA downregulated all of the ATM markers, i.e. CD16, CD31, 
CD163 and MMP-9. The mRNA expression levels were determined by RT-PCR and 
depicted as relative quantities (RQ) compared to the control (without PA; C). *, P < 0.05. 
M, mean. 
 
The inhibition of CD16, CD31 and CD163 was negatively associated with most of 
the indicators of obesity, while the inhibition of MMP-9 was positively associated 
(Figure 5). The basal levels of CD16, CD31 and MMP-9 in the unstimulated 
human adipose tissue explants were positively associated with at least one of the 
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indicators of obesity, while the level of CD163 was negatively associated with all 
of the indicators (Figure 6). To determine the contribution of adipocytes we 
investigated whether they express these markers. These adipocytes were obtained 
via the differentiation of omental preadipocytes. As depicted in Table 3, the mRNA 
expression of CD16 was not detected in adipocytes; while it was expressed by 
adipose tissue (CT = 32.2). CD31, CD163 and MMP-9 mRNA molecules were 
expressed in adipose tissue 1859-, 628-, and 2418-fold higher, respectively than in 
adipocytes (Table 1; P < 0.05) providing evidence that, at least partially, ATM 
contribute to the observed anti-inflammatory effects of PA, but not adipocytes.  
Figure 5: The association between the indicators of obesity and the response of adipose 
tissue macrophage related markers to PA treatment. OAT explants of each subject were 
incubated in triplicate with or without 3 mM PA for 24 hours. Results are depicted as a 
percentage of inhibition compared to the control (without PA; C), which was set to a 100%. 
The correlation coefficients (R) were determined between percentage of inhibition and the 
indicators of obesity, i.e. BMI, WC and WHR. The inhibition of CD16, CD31 and CD163 
was negatively associated with these indicators, while the inhibition of MMP-9 was 
strongly positively associated. 








Figure 6: The association between the indicators of obesity and the basal mRNA level of 
adipose tissue macrophage related markers. OAT explants of each subject were incubated 
in triplicate with or without 3 mM PA for 24 hours. The mRNA expression levels were 
determined by RT-PCR and depicted as ΔCT, which is calculated by subtracting the cycle 
threshold (CT) of each gene from the CT of the house keeping gene (GAPDH). The 
correlation coefficients (R) were determined between the values of ΔCT and the indicators 
of obesity, i.e.  BMI, WC and WHR. The basal level of CD16, CD31 and MMP-9 were 
positively associated with at least one of these indicators, while CD163 was strongly 
negatively associated with all of indicators.  
 
Table 3: Comparing the expression of adipose tissue macrophage markers between human 
primary adipocytes (HPA) and adipose tissue 





CD16A ND 31.7  
CD31 33.2 22.3 1858.8 
CD163 32.6 23.3 628.4 
MMP-9 34.8 23.6 2417.7 
CT, cycle threshold. *P < 0.05 vs HPA for all mentioned genes. 
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4.3.2   Propionic acid positively influences factors associated with 
insulin sensitivity in human adipose tissue explants  
 
The anti-inflammatory influence of PA on the adipose tissue may provide a 
mechanistic explanation as to the preventive influence of diets leading to the 
microbial production of SCFA on the development of metabolic syndrome (32;33). 
If this notion is true, however, PA should negatively influence the associated-
markers of metabolic syndrome. Therefore we decided to study the effects of PA 
on markers associated with adipogenesis, lipogenesis and insulin sensitivity in 
OAT explants. 3 explants per subject (taken from 4 women) were incubated with or 
without PA. It appeared that these explants all reacted to such treatment by 
significant upregulation of lipoprotein lipase (LPL; a lipogenesis marker) and sterol 
regulatory-element-binding protein-1c (SREBP-1c; another lipogenesis marker) 
mRNA expression by approximately 50% and 70%, respectively, while 
preadipocyte factor (Pref-1, an anti-adipogenesis marker) was significantly reduced 
by approximately 32% (P < 0.05) (Figure 7). GLUT-4, a factor associated with 
insulin sensitivity, was significantly induced by 75% (Figure 7).  
 







Figure 7: The influence of PA on the mRNA expression of lipogenesis, adipogenesis and 
insulin sensitivity related markers. OAT explants of each subject were incubated in 
triplicate with or without 3 mM PA for 24 hours. PA upregulated the expression of LPL, 
SREBP-1c and GLUT-4, while Pref-1 was reduced. The mRNA expression levels were 
determined by RT-PCR and depicted as relative quantities (RQ) compared to the control 
(without PA; C). *, P < 0.05. M, mean. 
4.3.3   Propionic acid acts on the adipose tissue partially through 
Gi/o-dependent signal transduction  
 
PA is a ligand for both GPCR41 and GPCR43, which both activate Gi/o-proteins to 
mediate PA signaling (19-21). As a consequence, we examined the role of the 
Gi/o-signal transduction pathway in the response of all examined factors in OAT 
toward PA treatment. As depicted in Figure 8, the treatment of OAT explants with 
the specific Gi/o inhibitor, pertussis toxin (PTX), abolished the response of IL-10, 
MIP-1α, MIP-1β, RANTES, G-CSF, TNF-α, Pref-1 and SREBP1c. On the other 
hand, PTX-pretreatment did not abolish the response of adipose tissue with respect 
to IP-10, CD16, CD31, CD163, MMP-9, LPL and GLUT-4. As PTX sensitivity is  
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Figure 8: The involvement of Gi/o-signal transduction. OAT explants of each subject were 
incubated in triplicate with an inhibitor of Gi/o-protein (PTX) for 2 hours to block the Gi/o-
signal transduction, and then OAT explants were treated with or without 3 mM PA for 24 
hours. PTX abolished the response of IL-10, MIP-1α, MIP-1β, RANTES, G-CSF, TNF-α, 
Pref-1 and SREBP1c, while the others were not influenced. The mRNA expression levels 
were determined by RT-PCR and depicted as relative quantities (RQ) compared to controls 
(without PA; C). Data are represented as mean ± SEM. *, P < 0.05 vs C; #, P < 0.05 vs PA; 
‡, P < 0.05 vs PA+PTX. 








the defining hall mark of Gi/o-dependent signal transduction, these results show 
that the cross talk between PA and adipose tissue physiology is at least partly 
mediated through the activation of Gi/o-protein coupled receptors. 
4.4   Discussion 
 
The pathogenesis of obesity-related pathology is still only partly understood. 
Accumulating evidence, however, shows that the adipose tissue during obesity is a 
site of low grade inflammation. In the present study we showed that 
explants of human omental adipose tissue from obese patients produce substantial 
amounts of the most examined inflammatory mediators and that within this tissue 
various ATM-specific genes, like CD16, CD31, CD163 and MMP-9 are 
abundantly expressed, further supporting the concept that the human adipose tissue 
is a site of low grade inflammation.  
Obesity is associated with increased infiltration of macrophages into 
human adipose tissue (29), which are identified, as we mentioned earlier, via 
specific ATM markers. Chemokines are crucial for the attraction of mononuclear 
cells from the circulation into adipose tissue (34;35). Herein we demonstrated that 
PA downregulates the production of various chemokines, cytokines and ATM 
markers. In addition, ATM markers were either not detected or very low in 
adipocytes compared to adipose tissue. Taking together, this implies that non-
adipocyte cells, most likely ATM, contribute to the immunomodulatory effects of 
PA. 
It has been recognized before that the colonic microbiota can influence 
both the propensity to as well as the course of obesity-related pathology. 
Mechanisms identified in this process are that different species of the microbiota 
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may differ in their capacity to ferment ingested food components and that the 
fermentation products may differentially effect mucosal immunology and thus 
influence host health in a paracrine fashion (6;8). In the present study we show, 
however, that the microbiota does act in trans, via the release of PA.  Specific 
microbial species differ greatly in their capacity to produce PA from food. Since 
differences in the amount of PA produced will have implications for the 
immunological, lipogenic, adipogenic and insulin sensitivity effects of PA, our data 
show that the metabolism of the intestinal microbiota can have direct consequences 
on the physiology of distal adipose tissues. 
These data correspond well with other studies that show that diets that 
are likely to enhance the production of PA by the microbiota 
correlate with lower incidence and better outcome of metabolic syndrome 
and other obesity-related diseases (32;33). Furthermore, our observation that the 
diminished inflammation induced in the adipose tissue explants by PA is also 
accompanied by improved expression of factors associated with lipogenesis, 
adipogenesis and insulin sensitivity, leads us to hypothesize that PA produced in 
the colon may have a direct beneficial effect on the adipose tissue. Thus we feel 
that PA may constitute an important novel link between the microbiota and the 
physiology of adipose tissue.  
Two receptors for SCFA in general and PA in particular have been 
identified, GPRC41 and GPRC43. We observed the expression of these receptors 
in human adipose tissue (36), suggesting that the effects of PA on the adipose 
tissue might be mediated through these receptors. Support of this notion was found 
from our experiments that at least part of the responses to PA are sensitive to PTX, 
generally considered as a specific inhibitor of Gi/o proteins and hence suggesting 
that G-protein coupled receptors mediate the response to PA. In addition, genetic 
evidence exists that GPRC43 acts as an anti-inflammatory protein, because mice 
genetically deficient in active GPRC43 are prone to exaggerated inflammation in a 







variety of murine models. Hence GPRC43 is a likely candidate to mediate at least 
part of the response to PA in human adipose tissue and selective agonists for this 
receptor may hold promise for combating metabolic syndrome. Experimentation 
addressing this notion is currently under progress in our laboratory. 
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Introduction: Macrophages play a major role in the induction of inflammation, 
which is evidenced in a variety of modern diseases such as diabetes and 
inflammatory bowel diseases. The factors influencing macrophage-induced 
inflammation and subsequent pathology remain poorly understood. However, 
accumulating evidence suggests that the fermentation of dietary fiber by the 
intestinal microbiota appears to be protective. Short-chain fatty acids, e.g. 
propionic acid (PA), are the principal products of this fermentation. Therefore, we 
investigated the effects of PA on the secretome of human macrophages. 
Materials and methods: THP-1-derived macrophages were incubated for 2 hours 
with various concentrations of lipopolysaccharide (LPS) alone or with a 
combination of LPS and PA. Stable isotope labeling by amino acids in cell culture 
(SILAC) was employed to investigate changes in macrophage protein production 
in response to PA treatment. SILAC results were validated by ELISA. 
Results: In total 314 proteins were identified, 59 and 34 proteins were up-regulated 
and down-regulated respectively by PA treatment, of which 29 and 27 proteins 
were secreted respectively. The secreted down-regulated proteins belonged to 
various functional categories, among them inflammatory proteins (11 proteins). 
From these proteins, IL-8 and TNF-α, were validated by ELISA. Furthermore, 
ELISA showed that 6 other chemokines, which were below the limit of detection 
of SILAC, were also down-regulated. 
Conclusion: The negative cross-talk between PA, which is produced by the 
microbiota in humans, and the macrophage inflammatory process provides a new 
paradigm in understanding the relation between the microbiota and macrophages-
induced inflammation. 
 





    Chapter 5 
5.1   Introduction 
 
A large body of evidence shows that tissue-resident macrophages (1) are a 
contributing factor to the pathogenesis of inflammation associated diseases, 
including obesity (2;3), insulin resistance, diabetes (4), cardiovascular diseases 
(5;6) and inflammatory bowel diseases (IBD) (7). The etiology of these diseases is 
complex and involves not only macrophages, but also other biological and 
environmental factors. It has become clear that the microbiota composition and 
metabolic activity is an important factor in this respect. It has been reported that 
these factors influence the development of obesity (8;9), systemic inflammation 
(10) and IBD (11). The mechanisms by which colonic microbiota composition can 
have such consequences on inflammation and perhaps macrophages remain, 
however, obscure at best. 
 Dietary fiber intake is associated with a reduction in chronic inflammation and 
in intestinal inflammatory pathogenesis (12-15). This may be due to the 
fermentation of dietary fibers by the microbiota. Short-chain fatty acids (SCFA), in 
particular acetic, propionic and butyric acid, are the major microbial metabolites 
that are produced. Indeed inflammatory and clinical parameters of inflammatory 
bowel disease patients have been improved by SCFA enema treatments (16) 
through the inhibition of macrophage activation (17). However, butyric acid was 
studied the most (18), while little is known about propionic acid (PA).  
 Recently, it has been shown that PA possesses anti-inflammatory properties on 
human neutrophils and mouse colonic organ cultures (19). In addition, we have 
shown (20) and unpublished data) that PA influences the physiology of human 
adipose tissue, which is the principal site for obesity-induced inflammation. An 
important outcome of these experiments was that PA inhibited the production of 
inflammatory markers including adipose tissue macrophage (ATM) related 
markers. However, the effect of PA on macrophages has not been investigated yet. 
Therefore, we investigated the influence of PA on the secretome of macrophages. 







To achieve our aim we employed a proteomics technique (SILAC) to investigate 
the relative quantity of protein abundance in the secretome of treated (PA + LPS) 
versus control (LPS alone) macrophages and the outcome was further validated by 
ELISA.  
 
5.2   Materials and methods 
 
5.2.1   Materials 
 
RPMI-1640 media, light L-[12C6] arginine (L-Arg) and L-[12C6] lysine (L-Lys) 
isotopes, regular and dialyzed fetal bovine serum (FBS), proline, leucine, penicillin 
and streptomycin antibiotic mix, phorbol myristate acetate (PMA), PA, LPS, 
trifluoroacetic acid (TFA), dithiothreitol (DTT) and ammonium bicarbonate were 
purchased from Sigma (Zwijndrecht, The Netherlands), heavy L-[13C6] Arg and L-
[13C6] Lys isotopes were purchased from Cambridge Isotope Laboratories 
(Andover, MA, USA), SimplyBlue safe staining gels and MOPS buffer from 
Invitrogen (Breda, The Netherlands), carbamidomethylation and iodoacetamide 
from GE Health Care (Hoevelaken, the Netherlands), trypsin from Promega 
(Leiden, the Netherlands), acetonitrile (ACN) from Biosolve (Valkenswaard, the 
Netherlands) and formic acid (FA) from Merck (Schiphol-Rijk, the Netherlands). 
 
5.2.2   THP-1 cell culture 
 
Human THP-1 monocytes (kindly provided by the Department of Biochemistry, 
Academic Medical Centre Amsterdam) were maintained in RPMI-1640 phenol 
red-free media supplemented with 10% FBS, 100 U/ml of penicillin and 100 µg/ml 
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of streptomycin in humid atmosphere containing 5% CO2 at 37ºC. To induce 
monocyte-macrophage differentiation, THP-1 cells were plated at a concentration 
of 5*105 cells/ml and treated with 10 ng/ml PMA for 48 hours. THP-1-derived 
macrophages were treated for 2 hours, in triplicate, with various LPS 
concentrations alone (0.1, 1, 10, 100 and 1000 ng/ml) or in combination with 
various concentrations of PA (0.001, 0.01, 0.1, 1 and 10 mM). 
 
5.2.3   SILAC setup 
 
THP-1 cells were grown in RPMI media without standard L-Arg, L-Lys and 
phenol red and were divided into 2 experiments, SILAC-1 and SILAC-2. In 
SILAC-1, half of the THP-1 monocytes, which were considered control cells, were 
grown in medium supplemented with a light L-[12C6] Arg and L-[12C6] Lys 
isotopes while the other half of the cells, to be treated were grown in the same 
medium, but supplemented with the heavy L-[13C6] Arg and L-[13C6] Lys isotopes. 
In SILAC-2, cells were treated as in SILAC-1; however, the labels were switched. 
10% dialyzed FBS, proline and leucine were added to the culture of both SILAC 
experiments. Cells were grown for 8 weeks  in order to achieve near complete 
incorporation of the L-Arg and L-Lys heavy isotopes into proteins. Subsequently, 
cells were plated at a concentration of 5*105 cells/ml and treated with 10 ng/ml 
PMA for 48 hours to differentiate them into macrophage-like cells. Differentiated 
cells were treated for 2 hours with 1 µg/mL LPS and 10 mM PA and were 
compared to the control cells, which were treated with 1 µg/ml LPS alone.  
 
5.2.4   Protein Identification by LC-MS/MS  
 
Supernatants from approximately 25*106 THP-1-derived macrophages cells were 
harvested for the SILAC analysis. The cell-free supernatants were collected, 







concentrated by ultrafiltration and protein concentrations measured by the 
Bradford assay. Equal amounts of total protein from the control (LPS-treated) and 
the stimulated (LPS+PA-treated) groups were pooled together and were 
fractionated by SDS-PAGE on a 4–12% bis-Tris gel with a MOPS buffer system 
according to the manufacturer’s protocol (NuPAGE-Novex, Invitrogen). Proteins 
were separated for 50 min at 200 V, and staining of bands was performed 
overnight by SimplyBlue safe staining. Each lane was excised into 25 bands that 
were processed for tryptic digestion. Each band was cut into small pieces and 
stored at -20 °C until analysis. Then they were washed in ultrapure water and 
dehydrated in ACN. Each slice containing proteins was reduced with DTT (for 1 h 
at room temperature) and carbamidomethylation with iodoacetamide (45 min at 
room temperature in the dark). Gel pieces were subsequently washed with 
ultrapure water and ACN. Next, 5 µg/ml of modified trypsin (resistant to protolytic 
digestion) in 20 mM ammonium bicarbonate was added, and gel pieces were 
allowed to rehydrate on ice for 20 min. Digestion was carried out overnight at 37 
°C. After that, the peptides were extracted by adding 0.1% TFA and pure ACN and 
then the extract was dried via speed vacuum and resuspended in 5%TFA and 
50%ACN. The samples were dried again and resuspended in 0.1% FA to measure 
them by LC-MS/MS. 
 Separation of the resulting tryptic peptide mixtures was performed by 
nanoscale reversed-phase LC-MS/MS. The Agilent 1100 nanoflow/capillary LC 
system was equipped with a trapping column (5 x 0.3 mm, C18RP) (Dionex/LC 
Packings, Amsterdam, The Netherlands) and a nanocolumn (150 x 0.075 mm, 
C18PepMap) (Dionex/LC Packings). Peptides mixtures were injected into the 
trapping column at a flow rate of 20 µl/min (in 0.1% FA). After 5 min the trapping 
column was switched into the nanoflow system, and the trapped peptides were 
separated using the nanocolumn at a flow rate of 0.3µl/min in a linear gradient of 
elution from 95% A (0.1% FA) to 50% B (90% ACN, 0.1% FA) in 53 min 
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followed by an increase up to 80% B in 3 min. The eluting peptides were on-line 
electrosprayed into the QStar XL hybrid ESI quadrupole time-of-flight tandem 
mass spectrometer (ESI-qQTOF-MS/MS, Applied Biosystems, Framingham, MA; 
MDS Sciex, Concord, Ontario, Canada) provided with a nanospray source 
equipped with a Proxeon stainless steel needle (25-µm diameter). Typical values 
for emitter voltage were 2.25 kV in positive ion mode. Analyst QS 1.1 software 
(Applied Biosystems) was used for data acquisition in the positive ion mode 
typically with a selected mass range of 300–1500 m/z. Peptides with +2 to +4 
charge states were selected for tandem mass spectrometry, and the time of 
summation of MS/MS events was set to be 2 s. The three most abundant charged 
peptides above a 30-count threshold were selected for MS/MS and dynamically 
excluded for 30 s with 30-ppm mass tolerance. 
 
5.2.5   Data Analysis 
 
ProteinPilot 2.0 software (Applied Biosystems) was used to analyze the generated 
data. The search engine of the ProteinPilot makes use of the ParagonTM algorithm 
(21). Search parameters such as modifications, substitutions, cleavage events, and 
mass tolerance are modeled with probabilities and did not require user-controlled 
settings. Options that were chosen within the program were: amino acid 
substitution (label, Arg +6, Lys +6); Cys alkylation with iodoacetamide; digestion 
with trypsin; gel-based identification; species, Homo sapiens; identification focus 
for biological modifications; thorough search. The software automatically detected 
the heavy/light peak pairs and calculated the heavy/light ratios based on the peak 
areas.  
 The majority of average protein ratios reported by Protein Pilot have a P-value 
(evaluating the statistical difference between the observed ratio and unity) and EF 
(error factor) for each protein ID. The EF term indicates the actual average values 







lies between (reported ratio)/(EF) and (reported ratio) × (EF) at a 95% confidence. 
Only those protein matches having a P-value < 0.05, more specifically, if the 
protein was identified in the injection duplicates with P < 0.05, an average of the 
two ratios was calculated to represent its differential expression; otherwise, only 
the ratio with P < 0.05 was saved for that protein.  Afterwards, we selected those 
with error factor (EF) < 2 as ‘quantifiable entries’ with a variation below 20% (22; 
23). In addition, contaminant proteins that are present in the media but not 
produced by the cells were discarded. They were identified via switching the 
amino acid isotope labels as we mentioned earlier and consequently the ratios of 
contaminant proteins derived from SILAC-1 and 2 were hugely different.  
 Significantly changed proteins were analyzed by SecretomeP 2.0 (24) to 
identify the secreted proteins. Those proteins with a predicted signal peptide were 
considered as secreted via the classical pathway (endoplasmic reticulum/Golgi-
dependent pathway). If no signal peptide was predicted but the NN score exceeded 
the value of 0.5, proteins were classified as secreted via the non-classical pathway. 
Proteins that did not match these criteria were considered as being intracellular. 
Gene ontology analysis was performed using DAVID and STRING web tools and 
published knowledge. Default options were selected to analyze the protein function 
by the DAVID functional annotation clustering tool (25) and the threshold values 
of Enrichment Score (ES) was set at the default value (1.3). Functional analysis of 
the proteins was further studied by STRING with the high confidence setting. 
STRING is a database of known and predicted protein-protein interactions derived 
from genomic context, high throughput experiments, (conserved) co-expression, 
and published knowledge (26). 
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5.2.6   ELISA and multiplex 
 
Secreted cytokine and chemokine proteins were measured by single- and 
multiplex-ELISA assays according to the manufacturer’s description (R&D 
systems, Minneapolis, MN, USA and Bio-Rad, Hercules, CA, USA). 
 
5.2.7   Relative Q-PCR 
 
RNA isolation, cDNA synthesis and relative quantification of genes were 
performed as we described in our previous study (20). Primer pairs and probes for 
G-protein coupled receptor 41 (GPCR41) and 43 (GPCR43) were obtained from 
Applied Biosystems (ID numbers Hs00271131_s1 and Hs00271142_s1, 
respectively). The sequences of the primer pairs used for the housekeeping gene 
Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) were (5’-GGTGAAGGTC 
GGAGTCAACG-3’) and (5’-ACCATGTAGTTG AGGTCAATGAAGG-3’), 




5.2.8   Dose-effect of PA treatment on the secretion of TNF-α by 
human macrophages 
 
As a first step it was crucial to find out whether the PA receptors GPCR41 and 
GPCR43 were expressed by the THP-1-derived macrophages before investigating 
the effect(s) of PA on their secretome. As figure 1 illustrates, both of them were 
expressed and the quantity of GPCR43 mRNA was approximately 3 times higher 
than the quantity of GPCR41 mRNA (P < 0.0001). Their expression was 
significantly inhibited by approximately 21% and 50% respectively (P < 0.01) as a 







response to PA treatment. Subsequently, THP-1-derived macrophages were treated 
for 2 hours, in triplicate, with various LPS concentrations alone (0.1, 1, 10, 100 
and 1000 ng/ml) or in combination with various concentrations of PA (0.001, 0.01, 
0.1, 1 and 10 mM) to determine the dose-response relationship of PA on the 
secretion of TNF-α. As expected, TNF-α secretion increased with increasing LPS 
concentrations (Figure 2; 0 mM PA). Addition of increasing concentrations of PA 
led to a dose-dependent reduction of TNF- α secretion. As demonstrated in figure 
2F, average values of the relative quantities of all experiments were calculated and 
it was shown that 0.001, 0.01, 1.0 and 10.0 mM of PA inhibited significantly the 
secretion of TNF-α by approximately 22%, 31%, 53% and 79% respectively, while 
the effect of 0.1 mM PA was not significant. 
Figure 1: the basal levels of GPCR41 and GPCR43 mRNA expression (A) and their 
response to PA treatment (B and C). (A) The level of mRNA expression of GPCR43 in 
THP-1-derived macrophages was determined by RT-PCR and depicted as a relative 
quantity (RQ) compared to GPCR41 level. (B and C) THP-1-derived macrophages were 
incubated in triplicate with 1 µg/ml LPS alone or with a combination of 1 µg/ml LPS and 
10 mM PA for 2 hours. Expression of GPCR41 (B) and GPCR43 (C) are expressed as RQ 
compared to their expression before incubation with LPS and/or PA. Error bars represent 
±SD. *P < 0.01 vs. control. 
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Figure 2: Dose-response curves of PA on TNF-α secretion from THP-1-derived 
macrophages. THP-1-derived macrophages were treated for 2 hours, in triplicate, with 
various concentrations of LPS 0.1 (A), 1 (B), 10 (C), 100 (D) and 1000 ng/ml (E) and each 
of these concentrations was combined with or without various concentrations of PA (0.001, 
0.01, 0.1, 1 and 10 mM). F represents the averages of the magnitude of each effect that 
corresponds to each PA concentration occurring in the experiments of various LPS 
concentrations. The secreted quantity of TNF-α in the media was determined by ELISA 
and the results are depicted as absolute quantity (A-E) and as a RQ (F) compared to the 
control (LPS alone). Error bars represent ±SD. *P < 0.05, ‡P < 0.01, #P < 0.001 and §P = 
0.05 vs. control. 
5.2.9   Identification and relative quantification of macrophage 
secreted proteins using SILAC  
 
Based on the results above, we selected the extreme condition (1 µg/ml LPS-10 
mM PA) to increase the detection limits of SILAC; since, it is known that the 
technique does not easily detect the low abundant proteins such as some cytokines 
and chemokines. Based on our criteria (see materials and methods for details) a 
total of 314 non-redundant proteins were identified from both SILAC experiments, 







of which 243 proteins were overlapping (Table 1). It is known that PA has a mild 
effect (±25% - ±200%) on production of various parameters from various human 
cells and tissues, e.g. inflammatory parameters and adipokines production by 
colonocytes, neutrophils and adipose tissue (19;20); therefore, any protein with an 
average ratio either above 1.35 or below 0.65 can be considered showing a 
significant degree of up- or down-regulation compared with the mean (1.00). 
Figure 3 demonstrates the relative expression of all proteins and as summarized in 
Table 1 we found 59 and 34 proteins that were up- and down-regulated 
respectively. Later on, we predicted secreted proteins in the up- and down-
regulated identified proteins based on secretomeP software. There were 29 and 27 
secreted proteins up- and down-regulated, respectively. The list of those proteins is 
illustrated in Table 2.  
Figure 3: relative expression 
of all identified proteins. The 
314 proteins were plotted as a 
logarithmic fold change. 
Positive and negative values 
indicate an up-regulation and 
down-regulation, respectively, 
in the presence of PA. 
 
 
Table 1: Summary of the identified proteins in each data set. 




SILAC-1 305 56 32 
SILAC-2 252 42 26 
overlapping proteins 243 37 24 
Total nonredundant proteins 314 59 34 
secreted non-redundant 
proteins 
  29 27 
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Table 2: Differentially changed secreted-proteins.  
Accession 
number 
Name Average of the 
fold change 
P01375 Tumor necrosis factor (TNF)* 0.23 
P10145 Interleukin-8 (IL8)* 0.32 
O14773 Tripeptidyl-peptidase 1 (TPP-1)# 0.39 
P07711 Cathepsin L1 (CTSL1)# 0.4 
P07602 Proactivator polypeptide (PSAP) 0.46 
P01033 Metalloproteinase inhibitor 1 (TIMP-1)# 0.47 
P28799 Granulins (GRN)* 0.47 
P12109 Collagen alpha-1(VI) chain (COL6A1)# 0.48 
A6NC86 Uncharacterized protein ENSP00000244321  0.5 
P36222 Chitinase-3-like protein 1 (CHI3L1)*,# 0.55 
Q15084 Protein disulfide-isomerase A6 (PDIA6) 0.55 
P07954 Fumarate hydratase, mitochondrial (FH) 0.56 
Q9BS26 Thioredoxin domain-containing protein 4 
(TXNDC4) 
0.58 
Q9Y240 C-type lectin domain family 11 member A 
(CLEC11A)* 
0.58 
O00754 Lysosomal alpha-mannosidase (MAN2B1) 0.58 
P01024 Complement C3 (C3)* 0.59 
P00746 Complement factor D (CFD)* 0.6 
P01023 Alpha-2-macroglobulin (A2M)*,# 0.62 
P14780 Matrix metalloproteinase-9 (MMP-9)*,# 0.62 
P61916 Epididymal secretory protein E1 (NPC2)* 0.62 
Q09028 Histone-binding protein RBBP4 (RBBP4) 0.63 
P01034 Cystatin-C (CST3)# 0.63 
P15144 Aminopeptidase N (ANPEP)*,# 0.63 
P07339 Cathepsin D (CTSD)# 0.64 
P07333 Macrophage colony-stimulating factor 1 receptor 
(CSF1R)* 
0.64 
P13489 Ribonuclease inhibitor (RNH1) 0.65 
P42704 Leucine-rich PPR motif-containing protein, 
mitochondrial (LRPPRC) 
0.65 
P11021 78 kDa glucose-regulated protein  1.35 
P84090 Enhancer of rudimentary homolog  1.39 
P60981 Destrin  1.4 
P61586 Transforming protein RhoA 1.45 
P24666 Low molecular weight phosphotyrosine protein 
phosphatase  
1.49 
Q13185 Chromobox protein homolog 3  1.5 
O75874 Isocitrate dehydrogenase [NADP] cytoplasmic  1.5 
P23588 Eukaryotic translation initiation factor 4B  1.52 
O60664 Mannose-6-phosphate receptor-binding protein 1  1.54 







Q9NQR4 Nitrilase homolog 2  1.54 
P29218 Inositol monophosphatase  1.55 
P08708 40S ribosomal protein S17  1.57 
Q9Y2S6 Coiled-coil domain-containing protein 72 1.61 
O15511 Actin-related protein 2/3 complex subunit 5  1.66 
Q15274 Nicotinate-nucleotide pyrophosphorylase 
[carboxylating]  
1.68 
P08865 40S ribosomal protein SA  1.69 
P63173 60S ribosomal protein L38  1.99 
P14625 Endoplasmin  2.11 
Q9HB71 Calcyclin-binding protein  2.13 
P84077 ADP-ribosylation factor 1  2.42 
Q13011 Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, 
mitochondrial  
2.48 
P62906 60S ribosomal protein L10a  2.83 
P35268 60S ribosomal protein L22  2.87 
P50502 Hsc70-interacting protein  3.58 
P40306 Proteasome subunit beta type-10  4.59 
P28070 Proteasome subunit beta type-4  6.12 
P28062 Proteasome subunit beta type-8  6.43 
P28072 Proteasome subunit beta type-6  6.46 
P28065 Proteasome subunit beta type-9  7.02 
*, proteins that belong to inflammatory proteins. #, proteins that belong to ECM 
remodeling proteins. 
 
5.2.10   Gene ontology analysis 
 
To assess differentially secreted proteins in the context of GO, we first applied the 
DAVID functional annotation clustering web tool to identify significantly over-
represented functional annotations (Table 3). Up-regulated proteins can be mainly 
and significantly clustered into 4 major categories, proteasome subunits, cell cycle, 
protein translation and regulation of cytoskeleton organization. The percentages of 
up-regulated proteins belonging to these categories were 16%, 19%, 19% and 13%, 
respectively. While such proteins may have been derived from dying cells, it is 
possible that either they, or their breakdown products, may be actively secreted. 
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For example, proteasome subunits and ribosomal proteins are well-known 
intracellular proteins; however it was shown that they can be secreted (27;28). 
Regarding the secreted down-regulated proteins, 74%, 66%, 22%, 19%, 22% and 
12% of these proteins significantly belonging to signal peptide, extracellular 
region, proteases, inflammatory response, regulation of cell proliferation and 
regulation of catabolic process, respectively (Table 3). Due to the fact that there is 
no single GO tool that can offer a complete picture for the functional annotations 
of a certain list of proteins (29), because each tool uses different public databases, 
we further analyzed the proteins by other tools, i.e. STRING, protein database 
(ExPASy), and by searching the published knowledge (Pubmed). However, 
because the functional annotations of down-regulated proteins had higher ES than 
of the up-regulated proteins (total ES = 24.63 and 11.99 respectively) and because 
they belong to more relevant physiological functions, the further analysis was 
focused on the secreted down-regulated proteins. Figure 4 demonstrates one major 
network determined by STRING, which is combined from 2 functional categories, 
inflammation and extracellular matrix (ECM) remodeling related proteins. This is 
in accordance to the DAVID output, however, based on all used tools the number 
of inflammation related proteins was increased to 11 proteins (Table 2), including, 
tumor necrosis factor-α (TNF-α), interleukin-8 (IL-8), granulins and complement 
C3, which were inhibited by approximately 77%, 68%, 53% and 41% respectively. 
Four of the inflammation related proteins were also shown (Table 2) to be involved 
in the ECM remodeling, i.e. aminopeptidase N ((ANPEP)) metalloproteinase 9 
(MMP-9), alpha-2-macroglobulin (A2M) and chitinase-3-like protein 1 (CHI3L1), 
which were down-regulated by approximately 40%. Six more proteins belonged to 
ECM remodeling only, Tripeptidyl-peptidase 1, cathepsin L1 (CTSL1), 
metalloproteinase inhibitor 1, Collagen alpha-1(VI) chain, cystatin-C (CST3) and 
cathepsin D (CTSD), which were inhibited by approximately 61%, 60%, 53%, 
52%, 37% and 36%, respectively (Table 2).  
 







Table 3: GO analysis results. 
Proteins 
response 







proteasomes subunits 5 4.06 1.63E-
08 
16% 
cell cycle  6 4.06 0.019 19% 







4 1.53 0.0027 13% 
signal peptide 20 9.73 1.26E-
10 
74% 
extracellular region 18 6.62 1.66E-
08 
67% 
Proteases 6 2.78 4.00E-
04 
22% 
inflammatory response 5 2.09 0.0025 19% 
regulation of cell 
proliferation 
6 1.82 0.013 22% 
downregulated  
regulation of catabolic 
process 
3 1.59 0.02 11% 
* The percentage describes the percentage of proteins that significantly belong to a certain 
functional annotation  
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Figure 4: STRING analysis of the down-regulated proteins. Accession numbers of the 
secreted proteins that were down-regulated by PA treatment (Table 2) were submitted to 
STRING to determine their functional relationship. Stronger relationships are represented 
by thicker lines. One major network with interconnected proteins belonging to 2 functional 
categories, i.e. inflammatory and ECM remodeling, was identified. For protein 
abbreviations see Table 2. 
Inflammatory and ECM 
remodeling proteins 
 







5.2.11   PA possesses immunosuppressive properties 
 
The above analysis strongly suggests that PA inhibits the secretion of pro-
inflammatory parameters from THP-1-derived macrophages. To investigate this 
further, the effect on the secretion of TNF-α and IL-8 along with 11 other 
inflammatory parameters was measured via multiplex-ELISA on samples derived 
from the same and other 2 validation experiments. These parameters can be 
subdivided into 3 groups. The pro-inflammatory cytokines, i.e. interleukin-12 (IL-
12) and TNF-α, the anti-inflammatory cytokines, i.e. interleukin-4 (IL-4), 
interleukin-10 (IL-10) and interleukin-13 (IL-13) and the pro-inflammatory 
chemokines, i.e. granulocyte-colony stimulating factor (G-CSF), IL-8, interferon-
gamma-induced protein (IP-10), monocyte chemotactic protein-1 (MCP-1), 
Macrophage Inflammatory Proteins-1α and -1β (MIP-1α and MIP-1β) and 
regulated upon activation, normal T cell expressed and secreted (RANTES). As 
depicted in figure 5, PA significantly inhibited the secretion of TNF-α and 
unexpectedly IL-10 by approximately 67% and 77% respectively (P = 0.0003 and 
P = 0.00006, respectively). This has been noticed also by other studies (our 
unpublished data) and (19). It is known that TNF-α induces the production of IL-
10, which acts as a negative feedback to inhibit the excessive production of TNF-α 
(19;30). This might contribute to the observed unexpected reduction of IL-10. 
Furthermore, PA had no effect on IL-4, while IL-12 and IL-13 were not detected. 
With respect to chemokines, PA significantly inhibited the secretion of G-CSF, IL-
8, MCP-1, MIP-1α, MIP-1β and RANTES (but not IP-10) by approximately 46%, 
44%, 47%, 40%, 38% and 25% respectively (P < 0.05). 
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Figure 5: The influence of PA on the secretion of chemokines and cytokines by human 
macrophages. THP-1-derived macrophages were incubated in triplicate with 1 µg/ml LPS 
alone or with a combination of 1 µg/ml LPS and 10 mM PA for 2 hours. Secreted 
quantities of chemokines and cytokines in the media were determined by multiplex-ELISA. 
Results are depicted as relative quantities (RQ) compared to the control (with LPS alone). 
Error bars represent ±SD. *P < 0.05 and ‡P < 0.001 vs. control.  
 
 








5.3   Discussion 
 
In the human host, PA is mainly produced via colonic fermentation of dietary fiber 
by the microbiota where its quantity was reported to be 20 mmol/Kg (31). The 
majority of the PA produced in the colon is absorbed, passes the colonocytes and 
the viscera, and drains into the portal vein, where its quantity was reported to be 
0.1 mM (31-33). PA can be partially metabolized by colonocytes; however, to 
what extent PA is utilized or interacts with visceral tissues has not been examined 
yet. Hence, various tissue resident macrophages, e.g. colonic, adipose and liver 
tissue macrophages, encounter and interact with different concentrations of PA. 
Although accumulating evidence suggests that PA exerts anti-inflammatory 
effects, its effect on macrophages has never been examined. Therefore, we 
investigated the influence of PA on the secretome of human macrophages by 
SILAC, a high throughput and robust assay, to quantify a broad range of proteins. 
We found in total 314 non-redundant proteins, of which 59 and 34 proteins were 
up-regulated and down-regulated, respectively by PA treatment. Of these, 29 and 
27 proteins were secreted, respectively. 
 The secreted down-regulated proteins belonged to various functional 
categories, among them the inflammatory proteins. We demonstrated that 11 
inflammation related proteins were downregulated and we validated two important 
proteins of these (TNF-α and IL-8) by ELISA. In addition, we analyzed the effect 
on other inflammatory parameters, which were under the limit of detection in the 
SILAC experiment, and we found that PA inhibits the secretion of 6 chemokines. 
These chemokines are known to be involved in the recruitment of macrophages 
into tissues, such as adipose tissue (34). Taken together, this suggests that 
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physiological concentrations of PA exert immunosuppressive properties on human 
macrophages, including the inhibition of the recruitment of further macrophages.  
Another interesting group of secreted down-regulated proteins is ECM remodeling 
proteins. We showed that 10 ECM remodeling proteins were down-regulated and 4 
of them belong also to the inflammation related proteins. This is not surprising, 
since many ECM remodeling proteins are involved in leukocyte influx, chemokine 
and cytokine activation and formation of a chemokine gradient; for example it has 
been shown that MMP-9 activates IL-1β, IL-8 and TNF-α (35-37), suggesting that 
even though some cytokines and chemokines may still be secreted, PA still inhibits 
inflammation via inhibiting the activators (in this case ECM remodeling proteins) 
of these cytokines and chemokines. 
 Very recently, we have shown in one of our studies (unpublished data) that PA 
inhibited the production of various inflammatory parameters by human adipose 
tissue, including several cytokines, chemokines and markers of human adipose 
tissue macrophages (ATM). In addition, we found the expression of these ATM 
markers were not detected or very low in adipocytes compared to adipose tissue 
providing evidence that, at least partially, ATM contribute for the observed anti-
inflammatory effects of PA, but not adipocytes. In the present study our data 
strongly support this finding. 
 It is recognized that the microbiota can influence the pathogenesis of various 
inflammatory related diseases. However, it is still not fully understood how the 
microbiota can influence these. One possible mechanism is that the microbiota 
influences host energy regulatory genes and/or proteins. Indeed, Backhed et al (38) 
found that the microbiota-induced deposition of triglycerides in adipocytes was 
mediated via the inhibition of the expression of the fasting induced adipocyte 
factor gene (Fiaf) in mice, which is an inhibitor for the lipoprotein lipase. 
However, these authors did not determine how the microbiota interacts with the 
host genes and via which mechanism the microbiota influences the expression of 
the host genes. In the current study we show that PA might be the mechanism by 







which the microbiota may act on the host genes and thus providing a new paradigm 
in understanding the relation between microbiota and inflammation related 
diseases and suggesting that PA may have potential in preventing or treating 
inflammation related diseases. 
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Background: Obesity promotes inflammation in adipose tissue (AT) and this is 
implicated in pathophysiological complications such as insulin resistance, type 2 
diabetes and cardiovascular diseases. Although based on the classical hypothesis, 
necrotic AT adipocytes in obese subjects activate AT macrophages (ATM) that 
then lead to a sustained chronic inflammation in AT, to our knowledge, the link 
between human adipocytes and the source of inflammation in AT has not been 
studied systematically. So we decided to investigate human primary adipocytes 
alone to see whether they are able to prime an inflammatory state.  
Methods and Results: Using mRNA expression arrays, human pre-adipocytes and 
adipocytes were shown to express the majority of known cytokines/chemokines 
and their receptors, MHC II molecule genes and 14 acute phase reactants including 
C-reactive protein. A specific multiplex ELISA approach revealed the expression 
of 50 cytokine/chemokine proteins by human adipocytes. Upon lipopolysaccharide 
stimulation, most of these adipocyte-associated cytokines/chemokines and immune 
cell modulating receptors were up-regulated. In a migration assay, human 
adipocyte-derived chemokines attracted significantly more CD4+ T cells than 
controls and the number of migrated CD4+ cells was doubled after treating the 
adipocytes with LPS. Neutralizing the monocyte chemoattractant protein-1 effect 
produced by adipocytes, reduced CD4+ migration by approximately 30%.  
Conclusion: Human adipocytes express a large panel of cytokines/chemokines that 
are biologically functional. They are able to respond to an inflammatory stimulus 
and to activate CD4+ T cells independent of macrophages. This suggests that the 
primary event in the sequence leading to chronic inflammation in AT is a 
metabolic dysfunction in adipocytes, followed by production of immunological 
mediators by these adipocytes, which is then exacerbated by the activation and 
recruitment of certain immune cells.  
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6.1   Introduction 
 
An imbalance or dysfunction of AT contributes to obesity-induced chronic 
inflammation, which in turn results in energy metabolism disorders such as insulin 
resistance (IR), type 2 diabetes, inflammation and cardiovascular diseases (1-11). 
Although the involvement of adipocytes in energy regulation is clear, little is 
known about their role in the occurrence of inflammation in AT, which is assumed 
to be important in the development of type 2 diabetes. Notwithstanding the fact 
that AT is recognized as an immune organ and the ATM appeared to be the major 
source of inflammation in AT (10-15), there has been no systematic study on the 
role of adipocytes in inflammation. We hypothesized that obesity led to adipocyte 
dysfunction, which in turn primes an inflammation state, although this priming is 
not due to adipose tissue-infiltrated macrophages. In contrast, inflamed AT 
adipocytes may promote the infiltration of ATM and change the macrophages with 
a resident character (anti-inflammatory macrophages called M2 macrophages) into 
migrated macrophages’ phenotype (pro-inflammatory macrophages called M1 
macrophages) (11) through a paracrine action, thereby establishing a vicious 
environment that exacerbates the inflammatory pattern in the AT and, in particular, 
in adipocytes.  
 To test our hypothesis, we investigated whether the adipocytes synthesize 
immune-associated components and if so, whether these adipocyte-expressed 
immune genes and proteins are biologically active and functional. In this study, we 
used the state-of-the-art proteomics, genomics and microscopy techniques. 







6.2   Results and discussion 
 
6.2.1   Differentiation of pre-adipocytes into adipocytes 
 
To obtain a homogenous adipocyte fraction, human primary pre-adipocytes were 
differentiated into adipocytes (adipogenesis), which was morphologically 
monitored (Figure 1A-B). The efficiency of differentiation reached approximately 
90-95% as assessed by morphology, indicating that the adipocytes could be 
considered as a homogenous fraction. In addition, Illumina BeadArray showed a 
significant up-regulation of 4 mRNA markers of adipocytes, i.e. adiponectin 
(ADIPOQ; 1000-fold), perilipin (PLIN; 500-fold), adipose triglyceride lipase 
(PNPLA2; 32-fold), and fatty acid binding protein 4 (FABP4; 128-fold). All these 
four genes are involved in lipid metabolism and the hydrolization of triglycerides 
(4;5;16;17) and were highly expressed in adipocytes compared to pre-adipocytes 
(Figure 1C). Perilipin (the hallmark of droplet fat), was also shown and confirmed 
at protein level by immunofluorescent confocal microscopy (CLSM) (Figure 1D). 
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Figure 1: Differentiation of human pre-adipocytes into adipocytes. Panel A shows human 
pre-adipocytes (long, thin and flatted cells without detectable fat organelles). Panel B 
shows that differentiated fat cells (adipocytes) are spherical with differences in fat 
organelle size. Most space in adipocytes is occupied by fat organelles. Panel C displays 
differentiation markers for adipocytes. These markers are Adiponectin (AdipoQ), perilipin 
(PLIN), adipose triglyceride lipase (PNPLA2) and fatty acid binding protein (FABP4). 
Gene expression was expressed as log2 (e.g. the difference between pre-adipocytes and 
adipocytes for adiponectin expression is approximately 10, thus the true difference is 210 
(=1024-fold) and this is shown on the y-axis). Confocal laser scan microscopy (CLSM, 
confocal microscopy) was used to validate and localize perilipin protein in human 
adipocytes as shown in panel D. Fat organelles were stained with FITC (green color), 
indicated by orange arrow, and Perilipin was visualized with Texas red (red color) shown 
by white arrow. Perilipin was localized at the surface of fat organelles. 
 
6.2.2   Illumina (mRNA) BeadArray 
 
After establishing our experimental set up, we determined immune-expressed 
genes in pre-adipocytes and adipocytes by Illumina BeadArray. Intriguingly, both 







pre-adipocytes and adipocytes expressed the majority of known, immune-
associated cytokine and chemokine genes (Figure 2A-C), either pro-inflammatory 
like TNF-, IL-17, IL-19, CCL19 and CCL22  (6;9;11-13;15) or anti-inflammatory 
such as IL-4 and IL-13 (18;19). Based on the classical hypothesis, ATM is 
activated by triggers like lipopolysaccharide (LPS), which in turn produce pro-
inflammatory chemokines and cytokines such as TNF-, IL-6 and monocyte 
chemoattractant protein-1 (MCP-1; M1 macrophages). However, in our study we 
demonstrated that adipocytes can also contribute to the inflammation process.. 
Although no large differences were observed between pre-adipocytes and 
adipocytes with respect to expression of immune genes, IL-6 (pro-inflammatory) 
was only expressed in adipocytes, whereas IL-7 (a crucial role in T-cell 
homeostasis and could be considered as a new anti-inflammatory cytokine) was 
only expressed in pre-adipocytes (Figure 2A). Since human primary pre-adipocytes 
and adipocytes expressed substantial amounts of mRNA of many cytokines and 
chemokines, these immune genes seem to be an intrinsic property of this cell type. 
In the mRNA BeadArray we also found that both pre-adipocytes and adipocytes 
synthesize many cytokine and/or chemokine receptors (Figure 2A-C). Furthermore, 
a significant negative correlation was seen between cytokine expression levels and 
the expression of their corresponding receptors (P<0.0007; r= -0.5), except for IL-
18, for which both the cytokine and its receptor mRNA were highly expressed 
(Figure 2D).  




















Figure 2A-C: Illumina gene profiling analysis of the cytokines and chemokines and their 
receptors expressed by the human adipocytes and preadipocytes. Illumina results were 
derived from two independent experiments. Each experiment was done in duplicate. Gene 








Figure 2D: the correlation between the cytokines and their receptors.  
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6.2.3   Proteomics, multiplex ELISA, confocal and 
immunoelectron microscopy 
 
A proteomics approach was used to further validate the gene expression data. So 
far, all proteomics studies aiming at analyzing the adipocyte proteome have been 
performed in murine 3T3-L1 cells or in rat adipose cells (20) . A proteomic study 
of human primary adipocytes has not been reported before. Hence, a combination 
of different proteomics techniques, including LTQ-Orbitrap XT and Q-STAR, 
were used to analyze the production of cytokines and chemokines by human 
adipocytes. Although this approach led to the identification of approximately 1800 
proteins, no cytokine or chemokine proteins were identified except for acute phase 
proteins. This is presumably due to their low abundance and the current mass 
spectrometry analyses/ sample processing is apparently not sensitive enough to 
detect such low abundances. Therefore, a very sensitive, multiplex ELISA with a 
panel of 50 cytokine and chemokine proteins was used to analyze whether these 
proteins are synthesized by human adipocytes. This resulted in the detection of all 
50 cytokines and chemokines present in this panel in human adipocytes (Figure 
2E-G). To investigate whether these cytokines and chemokines are biologically 
active, the differentiated adipocytes were stimulated with LPS (200 ng/ml with a 
final concentration of 1 µg for 24 h). Adipocytes treated with LPS led to the up-
regulation (2E and 2F) of the majority of cytokines and chemokines, while a small 
fraction was down-regulated (Figure 2G). All of the up-regulated cytokine and 
chemokine proteins were pro-inflammatory (e.g. IL-6, TNF-α, MCP-1, IL-8) 
(Figure 2F), whereas a few down-regulated cytokines and chemokines were 
established anti-inflammatory (e.g. IL-7, IL-10 and IL-13) (Figure 2F and 2G). 
These results indicate that adipocyte-produced cytokines and chemokines are 
biologically active and might have a physiological relevance. Although no 
adipocyte-associated cytokines and chemokines were detected by the proteomics 
approach, this approach resulted in the identification of 11 known acute phase 
proteins (Table 1). Illumina BeadArray of human adipocytes confirmed the 







expression of the majority of these acute phase proteins at gene level (Table 1). A 
combined analysis of proteomics and Illumina BeadArray led to the identification 
of 14 established (21-24) acute phase proteins including  C-reactive protein (CRP) 
(Table 1), which is considered to be the most significant marker of inflammation. 
Both pre-adipocytes and adipocytes expressed the CRP gene, which was confirmed 
by RT-PCR analysis (data not shown). The fact that adipocytes synthesize CRP 
suggests that this gene was an intrinsic component of this cell. In addition, 
immunofluorescent confocal microscopy analysis using CRP-specific monoclonal 
antibodies (21) confirmed a substantial production of CRP at the protein level in 
adipocytes (Figure 3A-G). Immunofluorescent images were confirmed with 
immunoelectron microscopy using the same monoclonal antibody (Figure 3M-N). 
We focused our attention on the CRP because it plays an important role in host 
defense (immune-associated function) and elevated CRP levels are positively 
correlated to type 2 diabetes. CRP is also considered to be a prognostic marker in 
many diseases (22-24).  
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Figure 2E-F: LPS effect on the secretion of inflammatory parameter from adipocytes. (E) 
LPS upregulated the secretion of most inflammatory parameter by 1 to 3 folds and (F) 
above 3 folds and (G) down-regulated the rest of the parameters. The quantity of proteins 
was determined by multiplex ELISA protein BeadArray. Protein expression was expressed 
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P02787 136191 Transferrin TF Yes 6,81 77050 
P02751 2506872 Fibronectin FN1 Yes 5,45 282607 
P05121 129576 Plasminogen activator 
inhibitor-1 
Serpin A1 Yes 6,68 45060 
P35542 548885 serum amyloid A-4 SAA-4 Yes 9,27 14807 
P01024 1,20E+08 Complement C3 C3 Yes 6,21 87148 
P02794 120516 Ferritin heavy chain FTH1 Yes 5,31 21226 
P01019 113880 Angiotensiogen 
(SERPIN-A8) 
AGT Yes 5,87 53154 
P05155 124096 Plasma protease C1 
inhibitor 




SERPINA3 Yes 5,33 47651 
P18510 124312 Interleukine-1 receptor 
antagonist 
IL1RN Yes 5,83 20055 
P09919 4503079 Granulocytes-colony 
stimulating factor 
G-CSF3 Yes 5,61 22293 
P02741 5,60E+07 C-Reactive protein C-RP Yes 5,45 35039 
 








Figure 3A-G: Confocal microscopy analysis of C-reactive protein (CRP) in the human 
adipocytes. (A)  Adipocytes were not incubated with the monoclonal antibody against 
human CRP (negative control). (B) Adipocytes were stained with human CRP antibody and 
bound antibodies were displayed with alexa 647 coupled goat anti-mouse (B and E; red 
color). Fat organelle (lipids) was visualized with FITC (C; green color), and adipocytes 
were stained with DAPI to detect nuclei (D; blue color). A merge of all three labels is 
shown in (E). White and red arrows indicate the presence of CRP on cytoplasm and plasma 
membrane, respectively. (F and G) immunoelectron microscopy images of the CRP in 
human adipocytes. (F) was a negative control, while (G) was labeled adipocytes with CRP 
antibody and bound antibodies were displayed with coupled goat anti-mouse 15 nm gold 
particles. White arrow shows one CRP particle. 
6.2.4   Cell migration of CD4+ T cells, expression of MHC class 
II, and T cell co-stimulation genes by human adipocytes  
 
Together, these results suggest that human primary pre-adipocytes and adipocytes 
exhibit immune cell-like behavior. In addition, as depicted in figure 2 F-G and 4 A-
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B, adipocytes were found to express multiple receptors involved in T-cell 
(co)stimulation, especially upon treatment with LPS. These receptors included 
adhesion molecules, e.g. vascular cell adhesion molecule 1 (VCAM-1), 
intercellular adhesion molecule 1-3 (ICAM-1-3), the ligand CD62L (CD34), 
CD36, CD44, CD47 and CD58; receptors involved in antigen presentation (MHC 
class II), e.g. C2TA (= CIITA), HLADM, HLADP, HLADQ and HLADR, CD1C-
D, CD74 and CD4; receptors involved in T-cell co stimulation, e.g. B7.2 (CD86), 
CD2, CD38, CD40; as well as a significant number of cytokines and chemokines, 
e.g. MIP-1a, IFN-g, TRAIL, TNF-a, IL-8, RANTES, MCP-1, IP-10 and IL-6. It 
must be noted that many of these proteins have key functions in many aspects of 
the activation process leading to a cell-mediated immunity and, as such, are 
reminiscent of professional antigen-presenting cells (MHC II molecule) (25) . This 
observation led us to investigate whether human adipocytes exhibit an immune-cell 
function. We studied the role of human adipocytes in T-cell migration, which is an 
important requirement for allowing cell-mediated immunity. Since CD4+ T-cells 
are central to the regulation of cell-mediated immunity (25;26), we focused 
specifically on this cell population. We investigated the migration of CD4+ T cells 
towards human adipocytes (either treated with LPS or untreated) via the cell 
migration assay in a Boyden chamber (27) with a 5-μm-pore polyethylene 
terephthalate (PET) membrane (Millipore PET membrane insert for 12-wells,). 
CD4+ T cells were uploaded in the upper chamber (insert). As shown in Figure 4C, 
approximately 6000 CD4+ cells (assessed by counting of CD4+ in a Bürker-Türk 
chamber) (28) were migrated (after 10 h incubation) from the upper chamber 
towards the untreated human adipocytes (lower chamber), indicating that 
adipocyte-associated chemokines are functional. When human adipocytes were 
treated with LPS, the number of migrated CD4+ T cells approximately doubled 
(Figure 4C). We then investigated the role of the two most up-regulated 
chemokines (MCP-1 and IP-10) upon LPS stimulation (Figure 2F) in the migration 
of CD4+ T cells towards adipocytes. The effect of monocyte chemoattractant 







protein-1 (MCP-1) and IP-10 were neutralized by adding of monoclonal anti-body 
against human MCP-1 and IP-10 (α-MCP and α-IP-10) to the adipocytes treated 
and untreated with LPS. When α-MCP-1 was added to the adipocytes treated with 
and without LPS, the migration of CD4+ T cells dropped significantly by 
approximately 30%. Although the neutralization of IP-10 exhibited a slight 
reduction of CD4+ migration, this decrease was not significant for this chemokine. 
In addition to two independent migration experiments with similar results, we also 
performed one migration assay with similar conditions but with an incubation time 
of 30 h. Intriguingly, we found that adipocytes treated with LPS increase CD4+ 
cell migration by approximately ten-fold in a time-dependent manner (Figure 4D). 
This could be due to a potentially increased concentration of adipocyte-associated 
chemokines after 30 h incubation with LPS. 
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Figure 4A-B: The expression of the genes of MHC class II and receptors involved in 
(co)stimulation of T cells (A) and immune-associated cluster differentiation molecules 
(CD) (B), by human primary pre-adipocytes and adipocytes. Gene expression was given as 
log2 and shown on the y-axis. Illumina results were obtained from two independent 
experiments. Each experiment was done in duplicate. 
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Figure 4C and D: the influence of the adipocytes and some of their chemokines on the 
migration of CD4+ T cells. To determine the role of the adipocytes and their chemokines in 
chemoattracting CD4+ T cells, adipocytes were grown on the surface of the lower 
compartment of the culture plate, where they attached to the surface. Then they were 
treated with or without LPS (200 ng/ml) and with or without antibodies against MCP-1 and 
IP-10 (2 µg/ml) to neutralize the effect of these two chemo-attractants. Purified and rested 
CD4+ T cells were added to the upper chamber. The cells were incubated at 37ºC for 10 h 
(C) or 30 h (D). The number of migrated cells was obtained using Bürker-Türk chamber. 
This experiment was repeated twice and each experiment was done in triplicate. Error bars 
represent the standard deviations. The p-value obtained from an independent two-tailed test 
samples (T-test). P < 0.05 was accepted as statistically significant.  
 







6.3   Conclusion 
 
We have revealed that adipocytes express cytokines, chemokines, multiple 
receptors, cell adhesion molecules and MHC class II family involved in the 
(co)stimulation of T cell activation. Since adipocyte-associated immune 
components (genes and proteins) responded to LPS stimulation, these immune 
components are biologically active with a physiological relevance in adipocytes. 
The functionality of these adipocyte-synthesized components was confirmed by 
assessing the role of adipocytes in immune cell migration, using CD4+ T-cells as 
responder cells. Cell migration assay showed that adipocytes are able to activate 
CD4+ T cells. Thus, adipocytes dysfunction promotes inflammation via its own 
cytokine and chemokine synthesis machinery and is not dependent on invading 
macrophages. This immune cell-like function of adipocytes could play a direct role 
in the etiology of insulin resistance and type 2 diabetes.  
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7.1   General Discussion 
 
Recently, it has been shown that colonic fermentation of dietary fiber/resistant 
starch has beneficial and protective effects against obesity and its associated 
disorders. Short-chain fatty acids (SCFA), in particular acetic acid, butyric acid, 
and propionic acid (PA) are the primary products of this fermentation. SCFA have 
recently attracted considerable attention, because of their impact on the host’s 
health. However, most of the studies investigated the role of butyrate alone or 
mixed with other SCFA in colonic health and most of the few studies which 
considered PA alone were investigated in ruminants (chapter-2). While 90% of 
butyric acid is utilized by colonocytes and very little reaches the visceral tissues 
(1), the majority of the PA quantity produced in the colon (20 mmol/kg) (2) is 
absorbed, passes the colonocytes and the viscera, and drains into the portal vein. 
PA can be partially metabolized by the colonocytes; however, the quantity that is 
utilized by visceral tissues, e.g. omental adipose tissue, has not been examined yet. 
The quantity of PA in the portal vein in non-fasting humans was demonstrated to 
be approximately 0.1 mM (2-4). Together, it is fair to say that PA is a potential 
microbiota-derived metabolite to interact with the host physiology. 
Indeed, important evidence for PA to act as a regulator of body-wide 
physiology exists. In 2003, three independent studies found that PA is a ligand for 
both G-protein coupled receptors 41 (GPCR41) and 43 (GPCR43) (5-7). GPCR41 
and GPCR43, like other GPCRs, are linked to GTP-binding proteins (G-proteins). 
G-proteins serve as relay molecules functionally coupling the receptors to their 
downstream targets and include four major classes, namely Gs, Gi/o, Gq/11 and 
G12/13.   
Taken altogether, one could envision that PA could constitute the elusive 
link between colonic-microbiota metabolism and the physiology of human adipose 
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tissue, including inflammation, insulin sensitivity, lipogenesis and adipogenesis, 
and consequently the whole body energy homeostasis, prompting us to investigate  
this hypothesis, which resulted in 4 studies, as discussed below. 
 
7.1.1   The role of PA concentration 
 
As eluded to above, PA can be found in various places in the human body. 
However, its physiological quantities are not the same in these locations. PA 
concentration in the lumen of the human colon is the highest and it is 
approximately 20 mmol/kg (2). As indicated before, the majority of PA is absorbed 
and passes the colonocytes and the viscera to reach the portal vein where 90% of 
PA is taken up by the liver (8) and the rest is transported to the peripheral blood. In 
humans, PA quantities in portal and peripheral blood were shown to be 100 µM 
and 6 µM, respectively (2;3;8-12). However, the quantity of PA that interacts with 
or is taken up by visceral (omental) adipose tissue is not investigated yet, most 
probably due to technical and ethical issues. As a consequence, the dose-effect 
relationship of PA on adipokine expression was determined in chapter-3 ex vivo in 
adipose tissue. Leptin production was stimulated in adipose tissue by PA in the 
concentration of 1 and 3 mM, but not by 10 mM. On the other hand, resistin 
production was suppressed in adipose tissue by 3 and 10 mM PA.  Consequently, 3 
mM PA was used in studies described in chapter-3 and -4.  
The concentrations of PA that were needed to show the observed results 
were relatively high (chapter-3). This is in agreement with earlier studies. Wajner 
et al (13) determined that PA concentrations above 2.5 mM were required to 
reduce the proliferation of activated lymphocytes. Moreover, Curi et al (14) found 
that PA concentrations equal or more than 3 mM showed remarkably high 
inhibition of lymphocyte proliferation. The requirement for high PA concentration 
could be due to the need for low pH values; since pH decreases as PA 







concentration increases. However, in chapter -3 and -4, while the pH value of the 
media used for adipose tissue treatment remained neutral, PA was still effective. 
This is also in accordance with Brunkhorst et al (15) and Le Poul (5), who 
demonstrated that the activation of G-proteins by PA was not due to extracellular 
or intracellular pH.  
 
7.1.2   PA influence on the production of adipokines by human 
adipose tissue 
 
Adipose tissue is an essential endocrine tissue that produces various adipokines 
that act via autocrine, paracrine, endocrine and neuronal pathways to influence 
multiple physiological functions such as, satiety, energy balance, immunity and 
insulin sensitivity (16). Therefore, we determined in chapter-3 the influence of PA 
on the production of few adipokines, i.e. leptin, resistin and adiponectin, on both 
mRNA and protein levels in omental adipose tissue derived from 28 women.  We 
found that PA stimulated leptin, both on the mRNA and protein level, while it 
almost completely abolished resistin mRNA expression. On the other hand, 
adiponectin expression was not influenced. Induction of leptin by PA suggests that 
PA can contribute to the reduction of food intake and to the increase of energy 
expenditure, since leptin is a potent anorexigenic hormone (17). This notion is 
supported by human interventional studies, which showed that dietary 
supplementation of PA prolongs the satiety period (18;19). On the other hand, the 
inhibition of resistin suggests that PA may exert anti-inflammatory and insulin 
sensitizing effects, since it has been proposed that resistin is a pro-inflammatory 
and insulin resistance marker (20-23).   
As different adipose tissue depots may vary in adipokine secretion 
patterns, we also investigated the influence of PA on the production of these 
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adipokines by human subcutaneous adipose tissue. The response of these 
adipokines in subcutaneous adipose tissue was similar to omental tissue, although 
it was less pronounced. 
 
7.1.3   PA counteracts human adipose tissue inflammation  
 
PA exerts anti-inflammatory effects in a variety of model systems (as summarized 
in chapter-2). Concomitantly, it has become evident that adipose tissue 
inflammation is a principal factor in the pathogenesis of obesity related diseases. 
We reasoned that obesity-related inflammation might be a target for the 
microbiota-produced PA. This hypothesis was supported by the inhibitory effect of 
PA on the production of the pro-inflammatory adipokine (resistin), which was 
observed in chapter-3 and promoted us to further examine the effect of PA on the 
inflammation of adipose tissue in chapter-4. It was revealed that PA suppressed 
the release of the cytokine TNF-α and IL-10 and the chemokines, MIP-1α, MIP-1β, 
RANTES, G-CSF and IP-10 from adipose tissue. As chemokines are crucial for the 
attraction of mononuclear cells from the circulation into adipose tissue (24;25), our 
data suggests that PA could inhibit macrophages recruitment into adipose tissue. 
To further clarify this, we determined the effects of PA on the mRNA expression 
of ATM markers, CD16, CD31, CD163 and MMP-9 (26-29) by human adipose 
tissue. We found that the PA treatment significantly downregulated these markers. 
To clarify the role of human adipocytes we investigated the expression of ATM 
markers by adipocytes and we demonstrated that ATM markers were either not 
detected or very low in adipocytes compared to adipose tissue providing evidence 
that, at least partially, macrophages contribute to the anti-inflammatory effects of 
PA, and not adipocytes.  
 







7.1.4   PA possesses anti-inflammatory effects on the human 
macrophages 
 
The observation that the ATM contribute to the anti-inflammatory effects of PA, 
but not the adipocytes (chapter-4), persuaded us to further evaluate the role of the 
human macrophages. To accomplish that it was necessary to employ a powerful 
and robust assay, to quantify a broad range of proteins.  Consequently, we 
employed the “stable isotope labeling by amino acids in cell culture” (SILAC) 
proteomic assay to investigate the relative quantity of protein abundance in the 
secretome of treated (PA + lipopolysaccharide [LPS]) versus untreated 
macrophages (LPS alone) (chapter-5). The results generated by SILAC were 
further validated by multiplex-ELISA assay. Also here, in the human macrophages, 
PA showed profound anti-inflammatory effects. This was demonstrated by the 
significant inhibition of the release of 17 inflammatory proteins, such as TNF-α, 
IL-8, granulins, complement subunits and 6 chemokines, providing more evidence 
that supports the notion that the inhibition of adipose tissue inflammation by PA 
treatment did not originate from adipocytes, but rather from the resident 
macrophages. Moreover, 10 extracellular matrix remodeling (ECM) proteins were 
downregulated, 4 of these proteins belonging to the earlier group of inflammatory 
proteins as well. ECM remodeling proteins are involved in leukocyte influx, 
chemokine and cytokine activation and formation of a chemokine gradient, for 
example it has been shown that MMP-9 activates IL-1β, IL-8 and TNF-α (30-32). 
These observations further support the finding that PA exerts anti-inflammatory 
effects on human macrophages. 
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7.1.5   PA positively influences factors associated with insulin 
sensitivity, lipogenesis and adipogenesis  
 
The anti-inflammatory influence of PA on the adipose tissue may provide a 
mechanistic explanation as to the preventive influence of diets leading to the 
microbial production of such SCFA on the development of metabolic syndrome 
(33;34). If this notion is true, however, PA should negatively influence the 
associated-markers of metabolic syndrome. Thus, the effects of PA on several 
markers of adipogenesis, lipogenesis and insulin sensitivity were tested ex vivo in 
human adipose tissue. It appeared that human adipose tissue explants all reacted to 
such treatment by significant upregulation of the lipogenesis markers LPL and 
SREBP-1c (chapter-4), GLUT-4, a factor associated with insulin sensitivity 
(chapter-4), and the adiposity marker leptin (chapter-3), while it reduced the anti-
adipogenesis markers pref-1 and resistin (chapter-3 and -4). These data are in 
agreement with mice studies, where it was shown that PA induced adipogenesis 
and inhibited lipolysis of mouse adipocytes (35;36). Taken together, we 
hypothesize that PA could induce the storage of fatty acids in adipocytes by 
inducing lipogenesis and adipogenesis,  
 
7.1.6   Human primary adipocytes exhibit immune cell like 
behavior 
 
Although our studies so far suggest that adipocytes do not contribute to the effects 
of PA, this does not necessarily imply that adipocytes have no role in the 
inflammatory process in human adipose tissue. To unravel this, human 
preadypocytes and adipocytes were studied in depth by genomics and proteomics 
approaches (chapter-6). It was shown, by illumina mRNA array, that both 
preadipocyte and adipocyte express various cytokines, chemokines, multiple 







immune-related receptors, cell adhesion molecules and MHC class II family genes. 
The majority of these genes were shown, for the first time, to be expressed by 
preadipocytes and adipocytes. Interestingly, there were no large differences 
observed between preadipocytes and adipocytes with respect to the expression of 
these immune genes. Although proteomics approach identified approximately 1800 
proteins, no inflammation-related proteins were detected except acute phase 
proteins. This is because the abundance of the inflammatory parameters was below 
the detection limits of our proteomics analyses. Therefore, we employed multiplex-
ELISA assay and we found that adipocytes secrete all the examined (= 50) 
proteins. To determine whether adipocytes behave as immune cells we treated 
them with lipopolysaccharide and we found that they responded as immune cells 
by up-regulating the pro-inflammatory parameters and down-regulating the anti-
inflammatory parameters. Finally, we examined whether adipocytes are involved 
in the initiation of the inflammation process. To achieve that, we assessed their 
ability to recruit T-cells after stimulating them by LPS, in vitro, and indeed T-cells 
were recruited. Thus, adipocyte dysfunction promotes inflammation via its own 
cytokine and chemokine synthesis machinery and this is not dependent on the 
invading macrophages. This immune cell-like function of adipocytes could play a 
direct role in the etiology of insulin resistance / type 2 diabetes.   
 
7.1.7   The involvement of G-proteins coupled receptors 
 
As we mentioned earlier, PA is a ligand for both GPCR41 and GPCR43, however, 
their expression by human adipose tissue was shown to be controversial. For 
example, Le Poul et al (5) showed that GPCR41 and GPCR43 were expressed in 
human adipose tissue, while Hong et al (35) showed it was not expressed in 
adipose tissue. Furthermore, the adipose tissue depot was not specified in these 
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studies. Our results show that both human adipose tissue depots (omental and 
subcutaneous) expressed GPCR41 and GPCR43 mRNA (chapter-3). 
Subcutaneous tissue expressed approximately 10-fold higher amounts of each 
receptor than omental (chapter-3). The presence of these receptors on human 
adipose tissue suggests that they might mediate the effects of PA on the adipose 
tissue. Support of this notion was found from our experiments (chapter-3 and -4) 
where we showed that the responses to PA were mediated via Gi/o-dependent and 
–independent signaling pathways. Gq-protein could contribute to the observed 
Gi/o-independent signaling pathway, since GPCR43 was shown to be coupled to 
both Gi/o- and Gq-proteins (5-7). In addition, genetic evidence exists that GPCR43 
acts as an anti-inflammatory receptor (37). Therefore, GPCR43 is more likely to be 
a candidate receptor to mediate the anti-inflammatory effects of PA and selective 
agonists for this receptor may hold promise for combating metabolic syndrome.  
 
7.2   Concluding remarks  
 
In the present thesis, we demonstrate that PA exerts pronounced anti-inflammatory 
properties on human adipose tissue and macrophages ex vivo via Gi/o-dependent 
and independent signal transduction pathways. Furthermore, we show that PA 
treatment improves markers which could be linked to insulin sensitivity, 
lipogenesis and adipogenesis. Thus, we provide for the first time evidence that 
microbiological metabolites can influence the physiology of the human adipose 
tissue. 
It is well known that the microbiota can influence the development of 
obesity and its associated pathogenesis. Very recently, it was found in mice that the 
microbiota induced the deposition of triglycerides in adipocytes via the inhibition 
of the expression of the fasting induced adipocyte factor gene (Fiaf) (an inhibitor 
for the lipoprotein lipase) (38). However, these authors did not determine how the 







microbiota interacts and influences the expression of the host genes. In the current 
dissertation we show that PA might be the mechanism by which the microbiota 
may act on the host genes and thus providing a new paradigm in understanding the 
relation between microbiota and obesity and its related pathogenesis. Furthermore, 
it is tempting to suggest  that the modulation of PA quantity through dietary 
manipulation and  pre- and probiotics or supplementation of PA may have 
potential application in preventing obesity, suppressing low grade inflammation 
and protecting against its associated diseases, such as insulin resistance, type-2 
diabetes and cardiovascular diseases. 
 
7.3   Future perspectives 
 
Our data lead us to speculate that the observed stimulation of lipogenesis and 
adipogenesis processes result in the clearance or redistribution of fatty acids. This 
would lead to the observed inhibition of the production of chemokines and would 
consequently lead to the inhibition of the recruitment of macrophages to adipose 
tissue. This all could lead to the observed insulin sensitivity improvement. In 
addition, we speculate that the stimulation of lipogenesis and adipogenesis cause 
the observed induction of leptin, since it is a marker of adiposity. This induction 
may lead to prolongation of satiety and inhibition of food intake. However, these 
speculations need to be further investigated in the future, preferably in human 
interventional studies.  
PA mediates its signal via Gi/o-dependent and -independent signal 
transduction. However, many questions still remain unanswered and await further 
research. For example, why are there two GPCR receptors for PA and how do they 
interact with each other to convey PA signaling? Is the function of GPCR41 
different from that of GPCR43, and if not, then why are these 2 receptors 
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expressed, in some cases, in the same cell type (e.g. adipocytes)? Answering these 
questions would be promising in terms of discovering or creating new ligands that 
may result in segregated effects of each individual receptor, with different 
outcomes. Finally, the potency for PA is low and PA receptors need 
supraphysiological concentrations of PA in peripheral blood to mediate its effects. 
This raises the question whether GPCR41 and GPCR43 are the right receptors for 
PA under normal physiological conditions in peripheral blood. It is possible that 
PA as well as other SCFA act as surrogate agonists rather than endogenous 
agonists for GPCR41 and GPCR43, or it is possible that these receptors are only 
activated in certain pathological situations when the PA concentration is unusually 
high, such as gingival inflammation and propionic acidemia. This suggests the 
necessity to screen for stronger agonists that can be used in the future instead of 
PA or may be combining PA with other SCFA, for instance acetate. Another 
interesting combination would be PA and thiazolidinediones, although they are not 
ligands for PA receptors. Thiazolidinediones inhibit low grade inflammation and 
improve pathological parameters of type-2 diabetes; however, they lead to an 
increase in body weight. It is suggested that the inhibition of leptin by 
thiazolidinediones contributes to the increase in body weight. To overcome this, it 
is essential not only to prevent the inhibition of leptin production, but rather to 
induce it. Therefore, combining PA with thiazolidinediones could prevent the 
increase in body weight simultaneously to the improvement of pathological 
parameters of type-2 diabetes. 
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Obesity and its associated low-grade inflammation and pathological consequences, 
including insulin resistance, type-2 diabetes and cardiovascular diseases, pose a 
great challenge to the health systems nowadays. Adipose tissue is a primary site of 
obesity-induced inflammation which is emerging as an important biological 
contributor to the obesity-related diseases. Recently, it has become clear that life 
style factors, including nutrition, are as important as the biological factors in this 
respect. A large body of research indicates that dietary fiber appears to be 
protective. Moreover, accumulating evidence shows that the composition of the 
colonic microbiota is an important factor. However, the mechanisms by which they 
influence the development of obesity and its related pathophysiology remain, 
however, obscure at best.  
Fermentation of dietary fiber by the colonic microbiota is the primary 
source for the production of short-chain fatty acids (SCFA), in particular propionic 
acid (PA). Therefore, one could envision that PA could constitute the elusive link 
between colonic-microbiota metabolism and the physiology of human adipose 
tissue.  We investigated the influence of PA on the production of various markers 
of physiologically relevant functions by human adipose tissue ex vivo. It appeared 
that PA suppressed the production of various cytokines, chemokines and the 
adipose tissue macrophages (ATM) markers from adipose tissue. Moreover, it 
positively influenced the production of the markers associated with insulin 
sensitivity, lipogenesis and adipogenesis. This suggests that PA possesses anti-
inflammatory effects that provides a mechanistic explanation to the observed 






to the preventive influence of the dietary fiber on the development of the metabolic 
syndrome. 
We also determined the contribution of the adipocytes and macrophages to 
the observed anti-inflammatory effects of PA. We demonstrated that ATM markers 
were either not detected or very low in adipocytes compared to adipose tissue. This 
implies that non-adipocyte cells, most likely ATM, contribute to 
immunosuppressive effects of PA. To evaluate further the role of macrophages, the 
effect of PA on the secretome of human macrophages was investigated via a 
quantitative proteomics approach. PA showed again overall anti-inflammatory 
properties, which were demonstrated by the significant inhibition of the release of 
21 inflammatory proteins from the human macrophages. 
Although we suggested that adipocytes do not contribute to the effects of 
PA we found that both preadipocytes and adipocytes produce various inflammatory 
parameters. In additition, LPS-stimulated adipocytes induced and reduced the 
production of the examined pro-inflammatory and anti-inflammatory parameters, 
respectively, and they were shown to recruit CD+4 T-cells. This implies that 
adipocytes exhibit an immune cell like behavior and they contribute for the 
initiation of the inflammation that occurred in the human adipose tissue 
independent of the ATM. 
As PA is a ligand for both G-protein coupled receptors 41 and 43 
(GPCR41 and GPCR43) and as both receptors activate the relay molecule Gi/o-
protein, the last aim of our thesis was to unravel the role of Gi/o-protein in 
mediating the effects of PA in human adipose tissue explants. It was revealed that 
the response of all examined factors to PA treatment in human adipose tissue was 
either Gi/o-dependent or –independent signal transduction. 
 The results presented in this dissertation provide a new paradigm in 
understanding the relation between the colonic metabolism and adipose tissue 
physiology. Furthermore, our data suggests that the modulation of PA quantity 
may have potential application in suppressing low grade inflammation and 






protecting from its associated diseases, such as insulin resistance, type-2 diabetes 

















Obesitas en de daaraan gerelateerde ziektes zoals metabool syndroom, type 2 
diabetes en hart en vaatziekten hebben grote consequenties voor de hedendaagse 
gezondheidszorg. Vetweefsel speelt een sleutelrol in de obesitas gerelateerde 
ontsteking, dat tegenwoordig wordt gezien als een belangrijke biologische factor in 
de obesitas geassocieerde ziektes. Recent is duidelijk geworden dat ook life-style 
factoren zoals voeding een zeer belangrijke rol spelen. Veel wetenschappelijke 
gegevens geven aan dat voedingsvezels een beschermende rol spelen. Ook worden 
steeds meer aanwijzingen gevonden dat bepaalde bacteriën in de dikke darm een 
belangrijke rol spelen. Echter, het onderliggende mechanisme is nog steeds 
onbekend. Fermentatie van voedingsvezels door bacteriën in de dikke darm is de 
belangrijkste bron van korte keten vetzuren (kkv), waaronder propionzuur. Wij 
hebben de hypothese ontwikkeld dat propionzuur een rol speelt in de relatie tussen 
het metabolisme in de dikke darm en de ontsteking van het vetweefsel. Wij hebben 
het effect van propionzuur onderzocht op de verschillende functies van het humane 
vetweefsel ex vivo. 
Het bleek dat propionzuur de productie van diverse ontstekingsstoffen 
(cytokines, chemokines) en merkers van macrofagen (betrokken bij ontstekingen) 
kon remmen. Bovendien werden processen gestimuleerd die een positief effect 
kunnen hebben bij de ontwikkeling van obesitas geassocieerde ziektes (bv. insuline 
gevoeligheid). Dit suggereert dat propionzuur een anti-inflammatoir effect kan 
hebben dat de beschermende effecten van voedingsvezel op de ontwikkeling van 
het metabool syndroom kan verklaren. Vervolgens hebben we de bijdrage van de 
vetcellen alsmede de macrofagen in het vetweefsel onderzocht betreffende het  
anti-inflammatoir effect van propionzuur. O.a. met behulp van kwantitatieve 
proteomics is gevonden dat de afgifte van ontstekingseiwitten door de macrofagen 






we dat ook de vetcellen zelf een rol konden spelen in de ontsteking door het 
uitscheiden van diverse ontstekingsstoffen en deze vetcellen konden ook T-cellen 
rekruteren hetgeen wijst op een belangrijke rol in ontstekingsprocessen. Tenslotte 
hebben wij de rol van de G-proteïne gekoppelde receptoren 41 en 43 alsmede Gi-o 
proteïne in het effect van propionzuur op vetweefsel onderzocht. Het effect op de 
meeste ontstekingsfactoren is Gi-o afhankelijk, hetgeen door een specifieke 
remmer kon worden aangetoond. 
De resultaten in dit proefschrift werpen licht op het begrijpen van de 
interactie tussen dikke darm en vetweefsel fysiologie. Onze gegevens suggereren 
tevens dat het variëren van de propionzuur flux een mogelijke toepassing heeft in 
het onderdrukken van lichte en chronische ontsteking en daardoor beschermend 
werkt tegen metabool syndroom, diabetes type 2 en hart- en vaatziektes.  
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